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The National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) guidelines 
have defined a high density lipoprotein cholesterol (HDL-C) of <50 mg/dL in women 
and <40 mg/dL in men as a risk factor for cardiovascular disease.  Our research aim 
was to examine the relationship between untreated HDL-C levels below this 
recommended level on five year cardiovascular, stroke, and all-cause mortality in 
adults over 71 years of age.    
 
The Established Populations for Epidemiologic Studies of the Elderly (EPESE) is a 
prospective cohort study of community dwelling adults over 65 years of age in East 
Boston, MA; Iowa and Washington Counties, IA; New Haven, CT; and Durham, NC.  
The National Institutes of Aging (NIA) started EPESE to study health, social, 
psychological, and economic aspects of older adults’ lives through extensive annual 
interviews. The EPESE dataset is further enriched by serum measures including low-
density lipoprotein cholesterol (LDL-C), HDL-C, total cholesterol, triglycerides, 
glucose, BUN and creatinine, which were obtained at the sixth annual follow-up 
interview.   
 
Our primary outcome was all-cause mortality with secondary mortality outcomes of 
acute myocardial infarction (AMI), coronary artery disease (CAD) not AMI, and 
congestive heart failure (CHF).  The mean age of our cohort was 78.7 years with the 
majority being female (63.86%), white (88.15%), and married (52.80%).  Just over 
half (52.07%) of our cohort met the criteria for low HDL-C as defined by ATP III. Chi 
square and Fisher exact test were used to compare demographics (age, gender, race, 
marital status, education), clinical variables (history of MI, cancer, diabetes, angina, 
smoking, alcohol use), and functional variables (activities of daily living, gross 
mobility, cognitive status) at baseline and five year follow-up.  Cox proportional 
hazard models were created using a step-wise approach to assess the impact of low 
HDL-C on mortality.   
 
Low HDL-C was not significantly associated with crude all-cause (P= .413), AMI     
(P= .473), CHF (P= .259), and stroke (P= .345) mortality.  HDL-C was significantly 
associated with unadjusted CAD (P= .033) mortality.  However, after adjustment for 
demographics, clinical, and functional variables as well as the other blood values all 
outlined above, HDL-C was not associated with five year all-cause, AMI, CAD, CHF 
or stroke mortality with adjusted hazard ratios of (HR=1.03, 95% CI 0.90-1.18), 
(HR=1.09, 95% CI 0.70-1.71), (HR=1.33, 95% CI 0.91-1.92), (HR=1.07, 95% CI 0.63-
1.81) and (HR=0.80, 95% CI 0.51-1.27) respectively. 
 
In older community dwelling adults enrolled in EPESE, low HDL-C levels as stratified 
by current recommended guidelines (<50 mg/dL in women and <40 mg/dL in men) 
were not associated with increased risk of five-year cardiovascular, stroke or all-
cause mortality.  HDL-C alone may have minimal effect on future longevity in older 
adults due to competing risk and co-morbid conditions.  Further studies are required 
to determine whether the movement toward more aggressive lipid profile 
interventions specifically to raise HDL-C in older adults would prove beneficial in 
this growing segment of our population.   
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CHAPTER 1:  INTRODUCTION 
In the United States, cardiovascular disease (CVD) kills one person 
every 35 seconds or approximately 2,500 people every day (1).  Despite 
many medical and pharmacological advancements in cardiovascular 
medicine in the last fifty years, CVD remains our nation’s leading killer 
surpassing the next four leading causes of death (cancer, chronic 
respiratory disease, accidents, diabetes) combined (1). Older adults 
aged 65 years and up experience the greatest number of 
cardiovascular events and 83% of the associated mortality, putting 
them at particularly high-risk (1-3).  
 
Research continues to assess patients and examine how to best modify 
known risk factors including high cholesterol, particularly high low 
density lipoprotein cholesterol (LDL-C), high triglycerides, and low high 
density lipoproteins (HDL-C) through lifestyle and pharmacological 
interventions in an effort to curb the morbidity and mortality 
associated with CVD.  The focus of this research is to examine the 
specific role HDL-C plays as a predictor of mortality in this high-risk 
segment of the population composed of older adults.  
 
To get a broader sense of HDL-C, we will discuss it in several contexts 
starting with the molecule itself and its complex role in the 
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pathophysiology of arteriosclerosis. Next, we will examine the effects of 
HDL-C on the population level looking at the epidemiological data 
available.  Finally, we will carefully break down the interventional 
study data and look forward making note of the gaps still in need of 
more exploration. 
 
The Physiology and Pathophysiology of HDL-C 
Our understanding of the role of HDL-C has become more complex in 
recent years.  Long touted as the “good cholesterol”, HDL-C has been 
shown to have both anti-inflammatory and pro-inflammatory effects 
providing protection in some circumstances and enhancement of 
arteriosclerosis in others (4,5).  Its role in reverse cholesterol 
transport, in conjunction with the known antioxidant, antithrombotic, 
and anti-inflammatory properties of HDL-C, all likely contribute to its 
apparent protective benefits.  Likewise, the “paradoxical” negative 
effects of HDL-C are also related to these same biochemical pathways. 
 
The HDL-C particle pictured in figure 1is composed of a hydrophilic 
phospholipid outer layer with cholesterol and apolipoproteins 
enclosing a hydrophobic core of triglycerides and cholesterol esters 
(6,7). The majority (estimated at 60%-80%) of the apolipoproteins 
present are apo A-I and are thought to be antiatherogenic (6,8). 
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Meanwhile about 20% of the apolipoproteins are apo A-II, which have 
been shown to be proatherogenic in animal models (6,9).  The apo A-I 
containing HDL-C has been shown to play an important role in reverse 
cholesterol transport, which is summarized in figure 2 (6).  Reverse 
cholesterol transport allows for the removal of cholesterol from the 
vasculature followed by transport to the gonads and the adrenals for 
use in sterol production or to the liver and ultimately the bile through 
which it can be removed from the body (6,9,10). Reverse cholesterol 
transport specifically allows for the efflux of cholesterol from cell 
membranes into apo A-I containing lipid-poor pre-β1 HDL-C particles 
through the binding of apo A-I to the adenosine triphosphate-binding 
cassette transporter A-1 (ABCA1) in the cell membranes of the vessel 
walls (6,9). Following its incorporation into HDL-C particles, the 
cholesterol is esterified by lecithin cholesterol acyl transferase (LCAT) 
to form large, spherical α HDL-C particles (6).  Following esterification, 
the cholesterol can be delivered to sterogenic tissues (liver, gonads, 
adrenals) through a family of scavenger receptors (9).  Alternately, the 
particle can be acted upon by cholesterol ester transfer protein (CETP), 
so that the HDL-C ester is transferred in exchange for triglycerides to 
VLDL/LDL-C particles, which then make their way to the liver for 
removal from the body (9). In addition to its direct role in reverse 
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cholesterol transport, the function of HDL-C as an antioxidant and 
anti-inflammatory is essential in protecting us from CVD.  
  
 
Figure 1:  High Density Lipoprotein Cholesterol (HDL-C) Particle 
Image taken from <http://www.icb.ufmg.br/pat/imagem/esquema/hdl.jpg> (10) 5 
  
 
   
Apolipoprotein A-I interacts with the ABCA-1 receptor to encourage removal of cholesterol from the pool in the 
cells in the form of free cholesterol (FC) and phospholipids (PL) that can then be picked up by nascent HDL-C. 
This pre-ß HDL-C is transformed to mature α HDL-C. 
Image adapted from <http://www.images.md> 
Figure 2:  Reverse Cholesterol Transport 
6
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It is widely acknowledged that vascular inflammation plays an 
important role in arteriosclerosis because endothelial cells within the 
plaque produce pro-inflammatory cytokines and monocyte chemotaxis 
protein-1 (MCP-1) (9,11).  These cytokines and chemokines attract 
monocytes and enhance intimal proliferation, leading to further 
damage of the arterial wall.  HDL-C acts as an anti-inflammatory by 
inhibiting the production of these detrimental cytokines, notably 
tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) (4,8,12). 
Secondly, HDL-C acts to regulate the expression of leukocyte 
endothelial adhesion molecules (vascular cell adhesion molecule-1 or 
VCAM-1, intracellular cell adhesion molecule-1 or ICAM-1, and E-
selectin), thereby protecting the vascular endothelium from invasion 
by leukocytes and monocytes (4,8,12).  It is believed that HDL-C and 
apo A-I specifically accomplish this by binding and in turn neutralizing 
lipopolysaccarides and endotoxin; thus, preventing the release of 
cytokines and also inhibiting the activation of complement (8,9).  Since 
TNF-α and IL-1 are also known to promote coagulation and 
fibrinolysis, it has been speculated that HDL-C may have an additional 
protective benefit in inhibiting these processes (9).   
 
HDL-C plays another role in decreasing inflammation as an 
antioxidant capable of inhibiting phospholipid oxidation of LDL-C and 
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acting to scavenge other oxidized lipids, like lysophosphatidylcholine 
(Lyso-PC), that are toxic to the endothelium and smooth muscle cells 
(4,9,13). LDL-C is oxidized by fatty acid hypoperoxides and is known to 
contribute directly to vascular inflammation as well as to initiate the 
formation and propagation of fatty streaks (4,9,13). By protecting the 
endothelial integrity, HDL-C acts to prevent the progression of 
arteriosclerosis and helps to maintain the stability of already existing 
plaques to prevent rupture (8).  
 
However, in the setting of existing CVD, HDL-C can itself become 
oxidized by a tyrosyl radical (11,14).  Oxidized HDL-C has 
contradictory effects from improving plaque inhibition in mouse 
models to decreasing reverse cholesterol transport and even 
encouraging oxidation (11,14).  This picture can be further confounded 
by both acute (infection, as in sepsis or even influenza) and chronic 
(autoimmune disease, metabolic syndrome) systemic illnesses which 
are known to lower total HDL-C and encourage its inflammatory 
properties (4,15-17).  The mechanism behind this is thought to involve 
the binding of HDL-C to ceruloplasmin and serum amyloid A, both 
acute phase reactants, causing the particle to lose its apo A-I content 
and become pro-oxidative and pro-inflammatory (9).  Paradoxically, the 
pro-oxidative qualities of HDL-C in individuals with known CVD or 
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other illness can counteract its protective effects.  In age and gender-
matched controls, those with CVD possessed a greater portion of pro-
inflammatory HDL-C (identified by monocyte chemotaxis assay) 
despite similar overall levels of total HDL-C leading us to question 
whether it is the unfavorable ratio of inflammatory to anti-
inflammatory rather than overall HDL-C level that is truly to blame 
(5,18).  To parse this apart, we must look beyond the laboratory to 
population-based studies looking at the effects of HDL-C. 
 
Epidemiological Studies of HDL-C 
In the arena of epidemiological research, it has been shown as early as 
the 1950s that healthy men have higher levels of HDL-C than those 
with CVD (19). Since then, HDL-C has been shown to be an 
independent predictor of mortality in the middle-aged population in 
numerous studies (2,20-22).  The landmark epidemiological studies in 
this area include the Framingham Heart Study, Prospective 
Cardiovascular Munster (PROCAM) study, and Multiple Risk Factor 
Intervention Trial (MRFIT) (23-32).  Chronologically, we will examine 
their findings and ultimate impact on how physicians have 
approached HDL-C as a predictor of CVD in their patients. 
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The Framingham Heart Study was initiated in the 1940s with 5,209 
men and women from Framingham, MA and utilized biannual clinical 
exams, numerous anthropomorphic measures, blood chemistries, and 
continual surveillance for morbidity and mortality in an effort to 
determine the risk factors for CVD; as time went on, this study would 
ultimately include their offspring as well (1,23,31-33).  This 
groundbreaking study has provided us with the criteria used at the 
bedside and in the office to determine 10-year cardiovascular risk 
stratification, including age, blood pressure, smoking status, and lipid 
profile (1,2,34).   
 
Between 1965-1971, a fasting lipid profile including cholesterol and 
the lipoproteins was drawn in 2,815 men and women between 49 and 
82 years of age and 132 of these individuals would develop new onset 
CVD within 4 years (35).  Those with HDL-C less than 35 mg/dL were 
8 times more likely to develop CVD compared to those with HDL-C of 
65 mg/dL though application of measuring HDL-C using the 
methodology of the time could mean a 5 mg/dL error in either 
direction making risk stratification of those on the borderline difficult 
(35). The near linear relationship showing decreased risk of CVD with 
increasing HDL-C was proven through additional studies of this data 
on its own and pooled with other cohorts (36,37).  
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Low HDL-C was also shown to be highly correlated to increasing body 
weight and triglycerides and associated though not statistically 
significantly with glucose intolerance (35). This clustering of features 
was likely an early recognition of the combination of features now 
referred to as metabolic syndrome, which is defined by both the Third 
Report of the National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III, or ATP III) and the 
World Health Organization (WHO) as meeting 3 or more of the 
following criteria: fasting plasma glucose >110; abdominal obesity with 
waist-to-hip ratio >0.90 or BMI >30 or waist girth >94 cm; HDL-C <35 
mg/dL; triglycerides >150 mg/dL; and blood pressure >130/85 mmHg 
with the WHO requiring glucose intolerance as one of the three 
parameters (2,38,39).     
  
Also in an effort to identify cardiovascular risk factors, MRFIT was 
begun in the 1970s (40). It involved the screening of over 350,000 men 
between 35 and 57 years of age from 1973-1976 ultimately obtaining a 
cohort of 12,866 men without evidence of CVD for a longitudinal study 
(40).  The study population was randomized to a special intervention 
group receiving more intensive treatment for hypertension, dietary 
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counseling for lipids and smoking cessation counseling, or a second 
group receiving usual care delivered by their regular non-study 
physician (41). Studies of both arms of this cohort have shown a 
statistically significant inverse relationship between CVD mortality and 
HDL-C level (41). A non-significant trend was also noted for all-cause 
mortality (41). A meta-analysis done in the 1980s, which included 
both Framingham and MRFIT, also yielded similar results suggesting 
that HDL-C has the greatest effect on coronary heart disease (CHD) 
related events and deaths with little impact on all-cause mortality (42). 
Yet, this effect is powerful enough that a 1 mg/dL increase in HDL-C 
results in a 2-3% decrease in yearly CHD mortality (42).  
 
A study published in 2006 on a cohort of MRFIT suggests that 
metabolic syndrome may also be playing a driving role in the MRFIT 
HDL-C results in a similar way as with the Framingham data (43). 
They noted that among men with metabolic syndrome (41.9% of the 
sample), HDL-C showed a strong predictive relationship with CHD 
mortality (HR=1.45, CI=1.17–1.54), while it showed a much weaker 
association among those without metabolic syndrome (HR=1.02, 
CI=0.86–1.22) (43).   
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The PROCAM study was begun in Germany in 1979 with initial 
recruitment through 1985 to examine people for prevalence of 
cardiovascular risk factors and then longitudinally follow them and 
track cardiovascular mortality and morbidity with biannual 
questionnaires, a follow-up exam in 6-7 years and reviews of their 
death certificates (27,44). Participants were drawn from a self-selected 
sample of almost 20,000 volunteers aged 16-65 years who worked in 
52 different offices or authorities (27,44).  Measures included 
questionnaires, blood pressure readings, anthropomorphic data, 
electrocardiogram, and blood draws following 12 hours of fasting 
(27,44).   
 
The PROCAM data showed that although HDL-C level was independent 
of age, it remained 12 mg/dL lower in men compared to women (44). 
Further analysis of cardiovascular events was confined to men over 40 
years of age because other groups lacked an adequate number of 
events for study over the 6-year follow-up period (44).  This cohort of 
4,559 men aged 40-65 years, was broken into those with CHD (fatal 
and non-fatal MI or other sudden cardiac deaths) and those without 
CHD (4,221 men, living with no confirmed events) (44). There was a 
statistically significant difference  (P<.0001) in the mean HDL-C 
between the CHD (39.5 mg/dL) and non-CHD (45.2 mg/dL) groups 
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with a greater percentage of those with lowest HDL-C <35mg/dL 
present in the CHD group (45.2% versus 16.2% in non-CHD) (44). 
Those with HDL-C <35 mg/dL also made up the greatest portion of the 
CHD group (44).  This PROCAM study data has shown a four-fold 
increased risk of CHD in those with an HDL-C of <35 mg/dL (44).  
 
These three studies have provided invaluable information with regard 
to systematically defining cardiovascular risk factors and determining 
how to translate them into a schema of risk stratification with which a 
physician can readily identify high-risk patients before they suffer 
morbidity or mortality associated with CHD.  Likewise, all have shown 
that HDL-C is an independent risk factor inversely related to CHD 
mortality, particularly at levels below 35 mg/dL.  Yet they have 
provided us with data primarily looking at middle-aged adults 
comprising those in their 40s-60s (2,20-22,42,44).  Those over 65 
years of age experience the greatest number of cardiovascular events 
and deaths each year, so it is important to examine some of the 
literature devoted explicitly to this uniquely at-risk population (1-3).   
 
One such study is The Established Populations for Epidemiologic 
Studies of the Elderly (EPESE), which is a prospective cohort of 
community-dwelling adults over 65 years of age in East Boston, MA; 
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Iowa and Washington Counties, IA; New Haven, CT; and Durham, NC 
(45).  The National Institutes of Aging started EPESE to study health, 
social, psychological, and economic aspects of lives of older adults with 
extensive longitudinal follow-up along with morbidity and mortality 
surveillance (45).  Much of the research on this cohort has focused on 
the cognitive and physical functional data, as well as depressive 
symptoms and social interactions to determine what best predicts 
successful aging (46-51).   
 
The EPESE dataset is further enriched by serum measures including 
low-density lipoprotein cholesterol (LDL-C), HDL-C, total cholesterol, 
triglycerides, glucose, BUN and creatinine along with numerous other 
parameters, which were obtained at the sixth annual follow-up 
interview (52). This group is commonly referred to as the MacArthur 
cohort and has provided a well-defined group of people on which there 
is a wide breadth of lifestyle and health measures in addition to the 
serum values allowing research to place these quantitative measures 
in a unique context. 
 
Previous studies of EPESE population that have examined the 
predictive value of cholesterol and HDL-C yielded conflicting results 
(52,53).  The first found that serum cholesterol levels were not 
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predictive for cardiovascular disease (defined as coronary heart disease 
or acute myocardial infarction) or all-cause mortality in the very 
elderly (>80 years of age) (52).  Low HDL-C was associated with an 
increased risk of CHD, but these findings were not significant (52). 
   
Another study examined the predictive value of serum cholesterol and 
HDL-C for CHD mortality excluding individuals with a prior history of 
cardiovascular disease (52,53).  Low HDL-C (defined as <35 mg/dL) 
was shown to significantly increase risk of CHD in those 70-80 years 
of age with a similar trend of borderline significance in those >80 years 
of age (52,53).  Even HDL-C in the normal range (35-59 mg/dL) was 
associated with increased risk of death from CHD (52,53).   
 
These findings are in agreement with much of the data present in the 
middle-aged population suggesting the inverse relationship between 
HDL-C and cardiovascular mortality risk.  Likewise, the presence of 
this trend in those with normal HDL-C levels falls in line with the 
concept that an increased percentage of pro-inflammatory HDL-C may 
be present in those with CVD even if their total levels are relatively 
normal.  It also reinforces the finding that total cholesterol is not an 
independent risk factor in this age group.  Yet, there is no other 
current study looking at specific cardiovascular mortality outcomes in 
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the entire cohort with adjustment for functional health. This 
adjustment could theoretically serve as a proxy for general wellness; 
thus, providing new insight into the role HDL-C plays in this statin 
naïve population (54).    
 
Interventional Studies of HDL-C 
The first series of interventional studies looking at HDL-C took into 
account lifestyle interventions including exercise, smoking cessation, 
and weight loss (55).  As we have learned more about the physiology 
behind HDL-C and what it means at the population level, the whole 
cholesterol and lipoprotein landscape has been reshaped by lipid-
lowering medications.  
 
First, we will look at the effects of lifestyle modification on HDL-C level 
and CVD.  Next, we will examine the classes of lipid-lowering 
medications most notably HMG-CoA reductase inhibitors (statins), 
fibrates, and nicotinic acid looking specifically at their effects on HDL-
C.  Other lipid-lowering medications that are used, but have little to no 
effect on HDL-C, include bile sequestrants, cholesterol absorption 
inhibitors, and neomycin; thus, these will not be reviewed here. 
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Lifestyle interventions including smoking cessation, diet and exercise, 
and weight loss all affect HDL-C levels (55). It has been shown that 
≥20 cigarettes a day causes a dose-dependent reduction in HDL-C 
from 11-14% (55-57).  Body mass index (BMI) is also inversely related 
to HDL-C levels with lower levels found among those with higher BMIs 
(58). Regular exercise has been associated with higher HDL-C levels as 
well, but the greatest gains in HDL-C are shown in sedentary 
overweight individuals who engage in high levels of high intensity 
exercise rather than low levels of more moderate exercises (59,60). Of 
note, during active weight loss HDL-C levels appear to go down, but 
once weight stabilizes the HDL-C levels too appear to stabilize in 
accordance with the new weight allowing for an increase of 2 mg/dL 
for each 4.5 kg lost (61).     
 
In addition to lifestyle changes, lipid-lowering medications and other 
medications can also influence HDL-C levels (57).  Nicotinic acid, a 
niacin derivative, provides the greatest increase in HDL-C of 15-35% 
(57). Nicotinic acid discourages the production of very low density 
liporoteins (VLDL) and thereby lowers triglyceride levels (57). However, 
its effects on HDL-C are thought to be related to encouraging reverse 
cholesterol transport because nicotinic acid inhibits the removal of apo 
A-I from HDL-C particles without decreasing the removal of cholesteryl 
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esters by hepatocytes in vitro (57). The major side effect is flushing 
and can be controlled with time-release preparations and pre-
treatment with a prostaglandin inhibitor such as aspirin (57).  
Unfortunately, nicotinic acid can increase glucose intolerance and 
thereby diabetics must be carefully monitored (57). Also, in doses 
above 3 g per day there is an increased risks of liver function test 
abnormalities (57). Currently, niacin is often used in conjunction with 
another lipid-lowering medication, notably statins, to good effect as 
shown by the Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol (ARBITER) 2 study where extended 
release niacin was added to already existing statin regimens (62). 
 
Fibrates (gemfibrozil, fenofibrate) increase lipoprotein lipase activity 
and decrease triglycerides (57).  With the increased catabolism of 
triglyceride heavy particles, more raw materials are available for HDL-
C production allowing for a moderate 10-15% increase in levels (57). 
Fibrates are used fairly regularly and have also been used in 
conjunction with the statins for better lipid control. 
 
Hydroxymethylglutaryl coenzyme A reductase inhibitors (HMG-CoA 
reductase inhibitors), or statins, are the standard for lowering LDL-C, 
yet they have a only modest effect on increasing HDL-C of 5-10% (57).  
20 
 
 
 
The mechanism of inhibiting HMG-CoA reductase leads to a reduction 
in LDL-C receptors enhancing clearance of apo B containing 
lipoproteins (pro-inflammatory), thus preventing the transfer of 
cholesterol from them to apo A containing lipoproteins (57).  Though 
they have little effect on total HDL-C levels, statins have been shown to 
increase the ratio of anti-inflammatory to pro-inflammatory HDL-C by 
this mechanism (11).  Statins allow for the greatest impact on HDL-C 
in the setting of a very low level with a concurrently very elevated 
triglyceride level (57). However, in those with existing CVD, the change 
in the ratio of anti-inflammatory to pro-inflammatory HDL-C does not 
return to that of unaffected individuals (11).  Ultimately, the benefit of 
statin therapy for improved outcomes in CVD is evident, but it cannot 
be directly linked to this change in HDL-C function because there is 
also a concurrent change in LDL-C (63,64).  
 
In addition to those specifically designed to treat lipid disorders, there 
are other drugs that also affect HDL-C levels including α-blockers, 
estrogens, and alcohol (57).  Similarly to fibrates, α-blockers are 
thought to increase lipoprotein lipase activity to create an increase in 
overall HDL-C production (57). Estrogen in the form of oral 
contraceptives has also been shown to raise HDL-C levels 10-15% by 
increasing apo A-I production and encouraging lipase activity in 
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hepatocytes (57). Yet, estrogen can also significantly increase 
triglycerides known to often be elevated anyway in the setting of low 
HDL-C, so these drugs must be monitored carefully in these patients 
(57). Moderate ethanol intake has been shown to also raise HDL-C, but 
this effect is lost when consumption increases to levels seen in 
alcoholics and the positive effects are lost with cessation of alcohol 
consumption (57).  
 
Finally, we will review three of the major interventional trials that have 
examined the effects of various pharmacological interventions on HDL-
C level, namely the Veterans Affairs High-density Lipoprotein 
Intervention Trial (VA-HIT), the Bezafibrate Infarction Prevention (BIP) 
trial, and the Air Force/Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS/TexCAPS). 
 
VA-HIT is a trial designed to explicitly look at how treatment with 
gemfibrozil affects HDL-C levels with a primary outcome of nonfatal or 
fatal MI or other CVD related death (65). A cohort of 2,531 men ≤74 
years of age with CHD, an HDL-C level of ≤40 mg/dL, and an LDL-C 
≤140 mg/dL was recruited from 20 Veterans Administration medical 
centers across the country (65). The study population was notable for 
advanced age of 64 years, very low HDL-C with a mean of 32 mg/dL, 
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and a high prevalence of both diabetes (25%) and hypertension (57%) 
(65). The half of the cohort receiving 1200 mg gemfibrozil daily had an 
HDL-C increase of 6%, total cholesterol decrease of 4%, and 
triglyceride decrease of 31% with no significant change in LDL-C levels 
compared to the placebo control group following one year of treatment 
(65,66). This cohort showed that treatment of high-risk individuals 
with very low HDL-C and moderately elevated LDL-C can benefit from 
intervention showing a significant reduction of 22% in both CHD 
related death and nonfatal MI at 5-year follow-up (65). The VA-HIT is 
also unique because the effect of increasing HDL-C is not confounded 
by a concurrent decrease in LDL-C, which has independently been 
shown to decrease cardiovascular risk (66).  This interdependence of 
LDL-C, triglycerides and HDL-C in predicting primary CVD morbidity 
and mortality with gemfibrozil was also demonstrated by the Helsinki 
Heart Study (67). In addition, VA-HIT included a cost-benefit analysis 
showing that treatment with relatively inexpensive gemfibrozil would 
actually be cost effective in decreasing future health expenditures in 
this population (65). 
  
Similar to VA-HIT and its analysis with regard to primary prevention, 
the BIP study examines the effect of another fibrate, bezafibrate, on 
secondary prevention of CVD morbidity and mortality (67). At initiation 
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in 1990, the aim of BIP was to look at whether increasing HDL-C and 
decreasing triglycerides using bezafibrate would affect nonfatal MI 
rates and CVD mortality in those who have already had a nonfatal MI 
or established CAD, HDL-C level ≤45 mg/dL, and modestly elevated 
total cholesterol (67). Between the bezafibrate and placebo arms, there 
were 3,122 men and women between the ages of 45 and 74 who 
participated with just over 60% having a previous MI and 
approximately 30% with a history of unstable angina (67).  Those in 
the bezafibrate group experienced an 18% increase in HDL-C and a 
21% reduction of triglycerides (67). Despite these dramatic effects, 
bezafibrate did not demonstrate a significant difference when 
compared with placebo group in repeat nonfatal MI or CVD-related 
death over the mean 6.2 year follow-up period of this study nor in later 
studies looking at 7.9 year mean follow-up (67,68). It is believed that 
the addition of open-label lipid-lowering therapy in both the placebo 
(15%) and intervention groups (11%) may have been a confounding 
factor (67-69). Of note, the mortality benefit of bezafibrate’s effect on 
HDL-C was only evident in post hoc analysis of those with triglycerides 
≥200 mg/dL at baseline suggesting that triglycerides may be the force 
driving the apparent benefit of HDL-C in other studies (67). The 
differences between BIP and VA-HIT have been attributed to the clear 
differences between the study population with the VA-HIT population 
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being older with more co-morbidities, and more deranged lipid profiles 
compared to the BIP cohort (67-69).  
 
AFCAPS/TexCAPS placed special emphasis on examining the impact 
of HDL-C and other lipid molecules on CVD since this cohort had what 
was considered an average total cholesterol (180-264 mg/dL) and LDL-
C levels (130-190 mg/dL) prior to the revised guidelines recommending 
lower levels in 2001 (2,70). HDL-C levels for inclusion were ≤45 mg/dL 
for men and ≤47 mg/dL for women with triglycerides <400 mg/dL (70). 
This cohort of 6,605 men 45-73 years of age and postmenopausal 
women 55-73 years of age was treated with 20-40mg of lovastatin, an 
HMG-CoA reductase inhibitor, daily versus placebo (70). This 
intervention decreased the risk of acute major coronary events (AMCE) 
including fatal and nonfatal MI, unstable angina and sudden cardiac 
death with incremental changes in risk of 11% for each 5mg/dL 
change of HDL-C from baseline to one year follow-up (70). Yet this 
could also represent the effects of the broad benefit of statins lowering 
the total cholesterol and LDL-C level, as well as increasing HDL-C. 
However, within the mortality model LDL-C was not predictive of 
AMCEs following treatment and the more useful measures were 
lipoprotein components of HDL-C, namely apo B which was significant 
both at baseline and follow-up and apo A-I as a component of apo 
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B/A-I (70). So, in those at moderate risk for new events, apo B and apo 
A-I may be more useful measures to assess the effectiveness of 
treatment with a statin.   
 
Gaps in Knowledge 
There is a lack of both epidemiological and interventional data for 
HDL-C in older adults >65 years of age, especially when taking into 
account the more strict recommended guidelines for lipid treatment 
introduced in 2001 (70). Yet there is also a gap when it comes to 
understanding the unique circumstances and qualities of older adults 
and their impact on lipid levels as well. For example, functional status 
can have an overarching affect on other areas of an older person’s life. 
Higher functioning individuals who are more likely to be community 
dwelling and more mobile typically have higher HDL-C levels, which 
are negatively correlated with visceral adiposity (suggestive of 
metabolic syndrome) compared to their non-community dwelling age-
matched counterparts who have lower HDL-C levels showing no 
relationship to their waist girth (71,72).  Therefore, individuals capable 
of living independently tend to be in better general health with 
potentially better though not necessarily “ideal” lipid profiles as 
compared to their institutionalized counterparts who are more likely to 
be affected by chronic illness.  
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Similarly, those older individuals with multiple co-morbidities are 
more likely to be home bound or in a long-term care facility.  On a 
pathophysiological level, both acute and chronic systemic illness and 
inflammation, which are more often present in this population, can 
also play an important role in the progression of cardiovascular 
disease placing HDL-C in a setting where it may behave paradoxically 
to feed into this cycle rather than protect (4,11,14-17).   
 
It has also been shown that these same functional outcomes are 
important to determining which elderly patients may be at greatest 
risk for death over the next year since many experience a steeper 
decline in function prior to death (49-51). With this in mind, it is 
important to consider a different schema when setting lipid treatment 
goals in an older population where the focus may be less on a 
particular number and lengthened lifespan, but on the quality of those 
years gained without loss of functioning (47).  
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CHAPTER 2:   STATEMENT OF PURPOSE 
According to the 2000 United States Census, there are 26.5 million 
people over 70 years of age who make up about 9% of our country’s 
total population with the fastest growing segment being the oldest-old 
who are 85 years of age and up (73).   The population of older adults 
will only continue to grow as the first of the “baby boomers” turn 60 
years old in 2006 (74).  This group of 75 million individuals born in the 
post-World War II period from 1946-1964 represented 28% of the 
population in 2000 with the majority born between 1946-1950 (74).  It 
is clear that our society will face many new clinical and economic 
healthcare challenges as our population ages in the coming decades. 
For this reason, we will be forced to more closely examine and plan for 
the treatment and management of older adults especially with regard 
to the chronic complications of cardiovascular disease, which remains 
the leading cause of morbidity and mortality in our population.  
 
Many large-scale epidemiological studies defining over 200 risk factors 
governing cardiovascular disease have shaped both how we see our 
patients and how we view our role as a physician.  Now there is a new 
focus towards aggressive treatment and active prevention of 
cardiovascular disease and its life altering and life ending 
consequences (75-77).  Recommendations like the ATP III guidelines 
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serve to provide physicians with a benchmark consistent with current 
data in order to best manage their patients to achieve a reduction 
morbidity and mortality.  
 
HDL-C is an important independent clinical risk factor for 
cardiovascular disease in the middle-aged population as proven by 
epidemiologic data from large studies including the Framingham Heart 
Study, MRFIT, PROCAM, and others (2,20-22).  Despite this, data 
regarding the clinical utility of using HDL-C levels in the older adults 
(65 years of age) are scant and conflicting (52,53,78-82).  Statistical 
adjustments for cardiovascular risk factors and the common co-
morbidities including hypertension, angina, previous myocardial 
infarction, diabetes, cancer and smoking history have lead to 
conflicting results in cardiovascular disease mortality in this 
population. 
 
Similarly, the widespread use of lipid-lowering medications can also be 
a confounding factor for multiple reasons. As we have seen, several 
including niacin and fibrates can have significant effects directly on 
HDL-C levels (57,83). Many are also prescribed in the form of 
combination regimens, which can influence all plasma lipids and 
cause confounding effects with regard to lowering LDL-C levels (63,64). 
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LDL-C is acknowledged to be a strong predictor of cardiovascular 
morbidity and mortality independently, so it presents a difficulty in 
determining where the benefit is gained (2).  Finally, there is also the 
question of whether the statins provide additional anti-inflammatory 
benefits that may indirectly affect HDL-C levels (11).    
   
The EPESE data set provides a unique opportunity to determine the 
long-term prognostic importance of HDL-C in older adults.  As a large 
data set, which enrolled adults over the age of 71 years who were 
followed for over 10 years, EPESE provides a prospective cohort with 
detailed demographic, clinical, laboratory, and functional status data 
with which this important question can be answered.   This population 
was also mostly naïve to lipid-lowering therapies with only 1% being 
exposed to these types of medications allowing us to examine how 
untreated HDL-C levels influence mortality; thus, avoiding some of the 
confounding effects of the medications (54).  This aspect is of special 
importance as we look towards a future of more aggressive lipid 
management regimens with tighter therapeutic targets.  
 
Looking to current ATP III guidelines, it is important to examine what 
these cutoffs mean in terms of mortality for older adults with specific 
attention on HDL-C. We have stratified our population in accordance 
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with these guidelines for HDL-C of <50 mg/dL in women and <40 
mg/dL in men (2).  Our research aim was to examine the relationship 
between untreated HDL-C levels below this recommended level on five 
year mortality in adults over 71 years of age.  Our primary outcome 
was all-cause mortality with secondary mortality outcomes of acute 
myocardial infarction (AMI), coronary artery disease (CAD) not AMI, 
and congestive heart failure (CHF).  The serum measures including 
LDL-C, HDL-C, total cholesterol, triglycerides, glucose, BUN and 
creatinine along with demographics and clinical and functional 
variables provide information for appropriate statistical adjustment to 
account for both cardiovascular and other risk factors influencing 
mortality (52). With these methods, we aim to isolate as much as 
possible the effect of stratifying patients along current HDL-C goals in 
an effort to examine if these are reasonable guidelines for an older 
population. 
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CHAPTER 3:  METHODS 
Study Sample & Data Collection 
The Established Populations for Epidemiologic Studies of the Elderly 
(EPESE) was initiated in 1980 by the Epidemiology, Demography, and 
Biometry Program (EDBP) at the National Institutes of Aging to study 
health, social, psychological, and economic aspects of older adults 
(45).  EPESE incorporates cross-sectional data and continued annual 
surveillance of 14,456 older persons age 65 years and above (45). The 
timeline of study events is described as follows with a visual summary 
presented in Figure 3.  
 
Study participants were recruited from 3 communities: East Boston, 
MA (n=3809), Iowa and Washington Counties, Iowa (n=3673); and New 
Haven, CT (n=2812) between 1981 and 1982 with an additional 4th 
site in North Carolina (n=4162) added in 1986 (45).   In East Boston 
and the Iowa counties, the study participants were a representative 
sample of the total population ≥65 years of age (45); In New Haven, the 
participants were derived from a random sample of residents stratified 
by housing type and sex (45,52).   Between 80 and 84% of eligible 
persons in the three communities participated (45).    
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Participants were followed from 1981 to 1988 with annual in-person 
and telephone interviews.   During the in-person interviews (which 
were done at baseline and at the 3rd and 6th follow-up points), 
participants were asked about their health habits, functional status, 
chronic conditions, and hospitalization history and had their blood 
pressure measured at home (45,52).   
 
In 1987-88, blood samples were obtained from about 41% of the 
original participants ≥71 years of age providing 5,940 useful measures 
of various serum values and markers including total cholesterol, HDL-
C, triglycerides, glucose, BUN, and creatinine along with numerous 
others (52).   
 
  
 
Figure 3:  Established Populations for Epidemiologic Studies of the Elderly (EPESE) Timeline 
33 
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Demographic Variables 
The demographic variables in this study included age, sex, race, 
marital status, and education.  The author examined the questions 
available in the entire EPESE dataset for all sites and time points.  The 
answers for these demographic questions were then recoded as 
categorical variables for use in the statistical model.  Age was 
calculated from date of birth reported by patient at baseline.   Race 
was classed as white and non-white based upon participants’ self-
report.  Marital status was classed as married and not married  
(separated, divorced, and widowed combined) and changes in status 
were updated yearly.  Education level was classed as < 7 years  
(yes/no), which was chosen to correspond with the completion of 
elementary school.  The original text of these questions is included in 
Appendix 1.  These baseline characteristics are summarized in  
Table 1. 
 
Table 1: Baseline Demographics of the Study Cohort 
Baseline Demographics East Boston Iowa 
New 
Haven Totals 
   Number 1248 1939 997 4184 
   Sex, % Female 64.02% 64.98% 61.48% 63.86% 
   Race, % White N/A 94.64% 75.53% 88.15% 
   Mean Age, years 77.91 79.07 79.03 78.67 
   Marital Status, % Married 52.40% 59.62% 40.02% 52.80% 
   Mean Education, years  9.11  10.76   9.47 9.78 
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All eligible participants were ≥71 years of age at the time of the blood 
draw.  Persons eligible who declined the blood draw tended to be older, 
had more disability, were more likely to be hospitalized in the last 
year, but no differences between groups were noted for sex, education, 
smoking history, or recent diagnosis of cancer (53).    
 
Clinical Variables 
Clinical variables were obtained in conjunction with the EPESE study 
at set time points.  Seated blood pressure data was obtained three 
times taken at each in-person interview (baseline, follow-ups 3 and 6) 
in accordance with the Hypertension Detection and Follow-up Program 
protocol and calculated by taking the mean of second and third 
readings (52,84).  We calculated pulse pressure by finding the 
difference between the mean systolic and mean diastolic blood 
pressure.  Likewise, we calculated body mass index (BMI) using the 
participant’s weight in kilograms divided by the square of height in 
meters.   
 
The author used previous studies of CVD to create a pertinent list of 
clinically relevant covariates.   Many including cancer, diabetes, 
hypertension, and myocardial infarction were present in the EPESE 
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dataset as simple yes/no medical history questions with built in 
examples of lay explanations.  Previous studies utilizing EPESE and 
the EPESE dataset itself were used to determine the appropriate 
question to elicit the symptoms of unstable angina (52).  Medical 
history of cancer, diabetes, hypertension, angina, and myocardial 
infarction were self-reported (yes/no) at baseline and follow-up. The 
baseline characteristics are summarized in Table 2. The text of these 
inquiries is also included in Appendix 1.  The author added yearly new 
onsets of these symptoms or conditions over the five-year time period 
to the baseline to obtain complete numbers at 5 years.    
 
History of lipid disorders was not taken.  Lipid-lowering medication 
use was self-reported and found to be about 1% in previous studies 
affecting 46 of the 4128 participants (54), so this variable was not 
included in our analysis.   
 
Health related lifestyle covariates included alcohol (wine, beer, hard 
liquor) use in the previous month and smoking history obtained at 
baseline.   The author combined alcohol use of any type and classed it 
as a categorical variable (yes/no).  Past and present smokers were 
included in the variable for those with a history of smoking and this 
information was also recoded categorically (yes/no).   
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Table 2: Baseline Clinical Variables in Study Cohort 
Baseline Clinical 
Variables n (%) 
except where noted 
East  
Boston Iowa 
New  
Haven Totals 
Drank Alcohol (wine, 
beer, liquor) in last 
month 
753  
(60.34%) 
578  
(29.81%) 
529  
(53.06%) 
1860 
(44.46%) 
History of Smoking  542  (43.43%) 
516  
(26.61%) 
459  
(46.04%) 
1517 
(37.98%) 
BMI, mean  27.36  (± 4.72) 
26.24  
(± 12.50) 
26.74  
(± 17.87) 27.74 
Blood Pressure, 
Systolic >160 
128  
(10.26%) 
214  
(11.04%) 
114  
(11.43%) 
456  
(10.90%) 
Blood Pressure, 
Diastolic <90 
1165 
(93.35%) 
1719 
(88.86%) 
863 
(86.56%) 
3747 
(89.96%) 
Antihypertensive 
Treatment 
413  
(33.09%) 
621  
(32.03%) 
323 
(32.40%) 
1357 
(32.43%) 
History of   Diabetes 168 (13.46%) 
145  
(7.48%) 
112 
(11.23%) 
425 
(12.64%) 
History of    
Cancer 
195 
(15.63%) 
245 
(12.64%) 
137 
(13.74%) 
577 
(16.47%) 
History of MI 110  (8.81%) 
192  
(9.90%) 
103 
(10.33%) 
405 
(11.54%) 
Exertional Chest 
Pain 
37 
 (2.96%) 
41  
(2.11%) 
34  
(3.41%) 
112  
(2.68%) 
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Functional Variables 
Through the examination of the EPESE dataset of questions related to 
function, the author put together a representative set of validated 
instruments containing questions asked consistently through all study 
sites and available at both the baseline and 6th follow up time points.  
The functional covariates that were included were obtained through 
these instruments and assessed various levels of physical and 
cognitive functioning.   
 
Performance of activities of daily living (ADLs) was assessed by 
counting each task (bathing, dressing, toileting, transferring, and 
feeding) the participant had difficulty doing (85).  An ADL score of 0 
suggests no difficulty with any of these tasks, while a score of 5 
indicates problems with all of them.    
 
Gross mobility was determined by asking if the participant was able to 
do heavy work around the house, walk a flight of stairs and walk a half 
a mile (86).  Each difficulty was scored as 1 just as with ADLs on a 
scale of 0-3.    
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More complex physical performance was determined by noting 
difficulties with pushing or pulling a large object across the floor, 
stooping down, writing, and reaching for objects (87).  This was scored 
similarly with a scale of 0-4.   
 
Cognitive function was assessed with the nine question version of the 
short portable mental status questionnaire (SPMSQ), which assesses 
the participant’s orientation, memory, attention, and fund of 
knowledge (88).  Errors on the SPMSQ were recorded on a scale of 0-9.  
 
The baseline and follow-up mean scores on all these instruments are 
recorded in Table 3. The specific text of the questions sorted by 
instrument is included in Appendix 1.   
  
 
Table 3: Baseline and Follow-up 6 Functional Scores on 
EAST BOSTON IOWA NEW HAVEN TOTALS 
Functional Variables 
Baseline Follow-up 6 Baseline 
Follow-up 
6 Baseline 
Follow-up 
6 Baseline 
Follow-up 
6 
   ADL Difficulties  
   0-5, mean 0.003 0.002 0.004 0.017 0.009 0.037 0.010 0.019 
   Gross Mobility   
   0-3, mean 2.42 2.05 2.52 2.18 2.33 1.81 2.34 2.02 
   Physical Performance  
   Difficulties 0-4, mean 0.45 0.50 0.30 0.60 0.42 0.44 0.44 0.51 
   Cognitive Status  
   (SPMSQ) 0-9,  
   mean errors 
1.24 1.57 0.66 1.12 1.30 1.58 1.03 1.42 
4
0
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Blood Values  
Blood samples were obtained at participants’ homes in the morning 
following the interview and processed within 8 hours of collection 
(52,89).  These values are listed in full in Appendix 2.  Participants were 
non-fasting at the time of the blood draw, but fasting serum cholesterol 
and HDL-C values have been shown to correlate with post-prandial 
values in both normal controls (non-elevated at baseline) and those with 
baseline hypercholesterolemia (90,91).  Triglycerides and glucose 
measures are less reliable when taken in the non-fasting state. 
 
The cut-offs for blood values were chosen in accordance with the Third 
Report of the National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III, or ATP III) 
recommendations (2).  The blood cut-offs (yes/no) for: depressed HDL-C 
<40 mg/dL for men and <50 mg/dL for women, ideal triglycerides <150 
mg/dL, LDL <200 mg/dL (very elevated), impaired renal function BUN 
>40 mg/dL or creatinine >2 mg/dL, and impaired glucose tolerance 
glucose >110.   
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Outcome Variables 
Five-year all-cause mortality from the time of the blood draw is 
considered the primary endpoint.  Secondary endpoints include 
breakdown of the all-cause mortality into the categories of 
cardiovascular and stroke mortality.  Deaths classified as acute 
myocardial infarction (AMI), coronary artery disease (CAD) not AMI, and 
congestive heart failure (CHF) were considered cardiovascular in nature.   
Death certificates are obtained at all centers and the cause of death is 
reviewed and coded by a certified nosologist using the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) (52,92).  The inherent limitation of death certificate miscoding for 
cardiovascular causes of death, which is thought to approach 24% is an 
unavoidable limitation of this study (93,94).   
 
Statistical Analysis 
Most variables were classified categorically as outlined above.  For 
functional scales, the categorical responses (yes/no or 
correct/incorrect) were summed to create a composite score.  During 
the study period, the new onset of chronic conditions was accounted for 
by summing these new onsets annually and adding them to the 
baseline. 
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Chi-square and Fisher exact test were used to compare demographic, 
clinical, and functional variables at baseline and 5 years later.  
Univariate analysis of demographics, clinical variables, functional 
variables, and serum measures with cause of death was performed for 
both these time points.   Our group’s statistician programmed this 
analysis of the variables as defined by the author. 
 
A series of Cox proportional hazards models were developed in a step-
wise fashion to assess the association between low HDL-C cholesterol (< 
40 mg/dL in men and < 50 mg/dL in women) with five-year 
cardiovascular and all-cause mortality as outcomes.  Ties were handled 
using the Breslow approximation (95).  The potential confounders 
included in the adjusted model were those demographic, clinical and 
functional variables outlined above.   A best-fit modeling approach was 
also used to examine the impact of different independent variables on 
the model as shown in Appendix 3.  The programming of the model was 
written and executed by our group’s statistician and the modeling data 
was then used to determine the pertinent covariates necessary for a 
statistically sound, yet parsimonious final model.   All analyses were 
performed using SAS version 8.02 statistical software (SAS Institute, 
Inc., Cary, NC) and included in Appendix 4. 
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Limitations 
One limitation of this study is that it is observational and the data are 
now 12 years old and do not incorporate newer therapies now being 
used for hypertension, lipid and glucose control.  Even with the 
introduction of these new therapies, it is unlikely that the risk for such 
conditions has substantially decreased over time.  Since blood samples 
were obtained from 65% of participants, there are some differences 
noted between those who gave blood and those who did not.  Persons 
who refused were older, had more disability, and were more likely to 
have been hospitalized in the previous year, but no differences between 
groups were noted for sex, years of education, current smoking status, 
or recent diagnosis of cancer requiring hospitalization (53).   
Biochemical variables of interest (cholesterol, HDL-C, triglycerides) were 
obtained only once and within-individual variability could not be 
considered nor could changes be observed over time.   
 
Despite these limitations, EPESE is the most extensive existing 
database of older patients that prospectively obtained both biochemical 
data and functional data with extensive long-term follow-up.  The large 
population and the detail of clinical data already collected provides a 
basis for efficient statistical analysis to determine the value of HDL-C as 
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a predictor of clinical outcomes of an elderly population, which is often 
neglected in the arena of randomized clinical trials.   
 
Ethical Considerations 
Since data collection has been completed and EPESE is a closed data 
set, participant confidentiality was the greatest ethical concern in this 
research study.  All data examined by this study has already been 
coded by the main EPESE research center such that each individual 
has received their own number and is only identifiable by that number 
and by particular site area. Data meets HIPAA de-identification criteria.   
The data collection for the EPESE project has been closed at all sites in 
1991-2, but the mortality continued to be recorded and coded past that 
time by the EPESE research center. 
 
This study was approved by the Yale University School of Medicine 
Human Investigations Committee (Appendix 5, HIC Exemption from 
Review).   
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CHAPTER 4:  RESULTS 
Study Sample 
Total initial enrollment in EPESE included 14, 456 people over 65 
years; therefore, the eligible participants were ≥71 years of age at the 
time of the blood draw, which occurred at the 6th annual follow-up. 
Approximately 41% of this group agreed to provide blood samples.  
Those without a serum sample were excluded from analysis (n=8516).   
Since North Carolina 5-year mortality data was incomplete, these 
samples (n=1756) were also removed from analysis.  Likewise, those 
without complete serum measures of interest (total cholesterol, HDL-C, 
triglycerides, glucose, BUN, and creatinine) were also excluded (n=70). 
These exclusions are not mutually exclusive and are summarized in 
Table 4.  
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Table 4:    
 
Total Sample Number of 
Participants 
Total EPESE participants (4 sites) 14, 456 
EPESE participants w/ serum samples 
available 
5,940 
 
Exclusions: 
 
NC site complete 5 yr mortality from blood 
draw not available for final model 
1,756 
Participants w/ incomplete serum 
measurements 
70 
Total Exclusions* 1,812 
Final study sample (3 sites) 4,128 
* Exclusions are not mutually exclusive 
 
Each individual site cohort and total study cohort examined here are 
comparable in demographic and lifestyle characteristics, cardiovascular 
risk factors and prevalence of cardiovascular disease to the whole 
EPESE study population and respective site populations.  However, the 
North Carolina cohort (not included) with serum samples is primarily 
non-white and has a greater percentage of individuals with <7 years of 
formal education compared to the East Boston, Iowa, and New Haven 
cohorts used in this study.    
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Overall, the majority of participants included in the final study sample 
were female (63.9%) and of white race (88.2%, excluding East Boston 
where race data was not collected).  The mean age of these participants 
was 78.7 years of age, ranging from 70 to 103 years of age across the 
three sites.  This cohort achieved a mean of 9.8 years of formal 
education with 16% achieving  <7 years (elementary level) of education.  
52.8% of the participants were married.  The mean BMI was overweight 
at 27.7 kg/m2 with almost half (49.0%) of participants with a BMI >25 
kg/m2.  Over one-third (38.0%) of participants were current or former 
smokers.  11.5% had a clear history of acute MI at baseline or over the 
following 5 years.  Likewise, the history of diabetes mellitus and cancer 
were 12.6% and 16.5% respectively over this same time period.  These 
finding are summarized in Figure 4. 
  
 
 
45.49%
50.36%
39.10%
51.63%
16.47%
12.64%
63.86%
88.15%
52.80%
15.99%
49.04%
37.98%
32.43%
11.54%
3.78%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Glucose <110
BUN >40 or Cr >2
Triglycerides <150
LDL-C <200
Low HDL-C
Past MI
Cancer
Diabetes
Hypertension‡
Smoker
Overweight
Educ <7yrs
Married
White†
Female
* Characteristics at blood draw (follow-up 6), except as noted   
† Does not include E. Boston (n=1248), race was not collected 
‡ Reported at baseline interview 
Figure 4:  Characteristics of Study Cohort* 
4
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Blood values broken down by ATP III guidelines are also presented in 
Figure 4. The mean HDL-C was 48.3 (± 15.3) mg/dL with 52.07% of the 
cohort meeting our criteria for low HDL-C, which was 50 mg/dL in 
women and 40mg/dL in men. Similarly, half (50.36%) our cohort met 
our criteria of ideal triglycerides <150 mg/dL with a mean value of 
179.3 (± 111.8) mg/dL.  Very few (3.78%) met our criteria for renal 
insufficiency (BUN >40 mg/dL or creatnine >2mg/dL) with mean values 
of BUN of 19.9 (± 8.0) mg/dL and creatinine 1.3 (± 2.0) mg/dL.  glucose 
of 125.4 (± 56.4). Though not included in the final model due to its lack 
of predictive value, mean total cholesterol was elevated at 214.2 (± 43.3) 
mg/dL. A summary of these serum values and others is provided in 
Table 5.   
 
  
 
Table 5:  EPESE Serum Values by Site 
E. Boston (N=1248) Iowa (N=1939)  New Haven (N=997) Total (N=4184) LAB VALUES 
n Mean (±SD) n Mean (±SD) n 
Mean 
SD n Mean 
TRIGLYCERIDES 1211 184.5 (±110.94) 1931 179.8 (±117.73) 975 171.0 (±111.29) 4117 178.4 
CHOLESTEROL 1216 214.0 (±42.81) 1934 215.8 (±44.00) 983 214.9 (±44.11) 4133 214.9 
HDL-C 1215 46.5 (±14.79) 1934 49.3 (±14.69) 979 48.5 (±14.70) 4128 48.1 
WBC 1152 7.0 (±2.19) 1928 6.4 (±2.57) 866 6.7 (±2.71) 3946 6.7 
HGB 1152 13.4 (±1.50) 1928 14.2 (±1.48) 866 13.4 (±1.65) 3946 13.7 
HCT 1152 40.5 (±4.40) 1928 42.7 (±4.40) 866 40.9 (±4.81) 3946 41.4 
PLATELETS 1102 255.3 (±75.57) 1901 251.2 (±89.69) 840 269.1 (±87.21) 3843 258.5 
SODIUM 1212 139.2 (±7.04) 1932 140.5 (±4.50) 974 139.7 (±5.44) 4118 139.8 
POTASSIUM 1212 4.3 (±0.47) 1932 4.7 (±0.56) 974 4.4 (±0.59) 4118 4.5 
CHLORIDE 1212 101.8 (±6.20) 1932 102.7 (±4.55) 974 101.5 (±5.40) 4118 102.0 
BICARBONATE 1211 28.2 (±4.49) 1932 29.8 (±4.56) 975 34.9 (±6.94) 4118 31.0 
BUN 1212 20.4(±7.84) 1932 19.7 (±7.27) 975 20.5 (±8.57) 4119 20.2 
CREATININE 1212 1.4 (±4.27) 1932 1.2 (±0.36) 975 1.3 (±1.01) 4119 1.3 
GLUCOSE 1212 133.3 (±61.91) 1932 119.6 (±49.14) 975 124.0 (±56.08) 4119 125.6 
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Outcomes 
The distribution of the causes of death was similar in the EPESE cohort 
with serum samples as in the whole EPESE population.  Table 6 and 
Figure 5 illustrate observed 5-year mortality by different conditions.   
The specific mortality outcomes of AMI, CAD, CHF and stroke 
accounted for almost 40% of the deaths during the five years of follow-
up of both the cohort with serum samples (39.6%) and the entire 
EPESE population (39.7%).  Cardiovascular mortality including AMI, 
CAD, and CHF accounted for 471 deaths (7.9% mortality) or 31.4% of 
all deaths (n=1509) in the cohort with serum samples.  Stroke 
accounted for an additional 123 deaths (2.1% mortality) or 8.2% of all 
deaths in this group.   
 
  
 
Table 6:  Study Cohort vs. Full EPESE 5yr Mortality by Cause of Death    
 
Study Cohort 
5 Year Mortality by 
Cause of Death, n 
(%) E.  Boston 
(n=1248) 
Iowa 
(n=1939) 
New Haven 
(n=997) 
Total 
(n=4184) 
Full EPESE 
(n=14456) 
All Cause 288 (23.1%) 487 (25.1%) 268   (26.9%) 1043 (24.9%) 3492 (24.2%) 
Stroke 17 (1.4%) 52 (2.7%) 21 (2.1%) 90 (2.2%) 266 (1.8%) 
Acute MI 32 (2.6%) 56 (2.9%) 19 (1.9%) 107(2.6%) 477 (3.3%) 
CAD 36 (2.9%) 81 (1.4%) 32 (3.2%) 149 (3.6%) 407 (2.8%) 
CHF 26 (2.1%) 41 (2.1%) 13 (1.3%) 80 (1.9%) 235 (1.6%) 
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Figure 5:  EPESE 5-Year Mortality by Cause of Death 
54
 
55 
 
 
 
Figure 6 shows the breakdown of this mortality by low and high HDL-C 
levels.   Table 6 shows unadjusted results based on the Cox proportional 
hazards models.  An HDL-C of ≤ 50 mg/dL in women and ≤ 40 in men was 
not significantly associated with crude all-cause (P=.413), AMI (P=.473), 
CHF (P=.259), and stroke (P=.345) mortality.  HDL-C was significantly 
associated with unadjusted CAD (P=.033) mortality.  However, following 
adjustment for demographic, clinical, and functional covariates, the 
adjusted hazard ratios (HR) was no longer statistically significant or 
suggestive of any trend for all-cause (HR=1.03, 95% CI 0.90-1.18), AMI 
(HR=1.09, 95% CI 0.70-1.71), CAD (HR=1.33, 95% CI 0.91-1.92), CHF 
(HR=1.07, 95% CI 0.63-1.81) and stroke (HR=0.80, 95% CI 0.51-1.27) 
mortality.  The adjusted results are presented in Table 7.  HDL-C was the 
only serum value of interest not significantly associated with unadjusted all-
cause mortality as shown in Table 6.
  
 
Figure 6:  All-Cause and Cardiovascular Mortality by Cause of Death by High and Low HDL-C 
 
≥
≥
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Table 6:  Unadjusted  5-Year Cardiovascular, Stroke, & All-Cause Mortality 
UNADJUSTED Hazard Ratios (95% Confidence Intervals) and P-Values 
Serum Values 
(mg/dL) 
AMI CAD (not AMI) CHF Stroke All Cause 
1.17 (0.76-1.80) 1.48 (1.03-2.13) 1.34 (0.81-2.21) 0.80 (0.51-1.27) 1.06 (0.92-1.21) HDL-C Female <50  
& Male <40  P=.473 P=.033 P=.259 P=.345 P=.413 
1.09 (0.72-1.63) 1.51 (1.07-2.11) 0.84 (0.52-1.35) 1.22 (0.78-1.90) 1.51 (1.33-1.72) LDL <200 
P=.689 P=.018 P=.461 P=.383 P=.001 
0.57 (0.36-0.90) 1.37 (0.96-1.96) 1.51 (0.92-2.46) 0.70 (0.44-1.12) 1.17 (1.02-1.34) Triglycerides <150 
P=.015 P=.085 P=.101 P=.138 P=.025 
2.69 (1.35-5.38) 2.63 (1.45-4.79) 8.25 (4.68-14.55) 3.56 (1.71-7.44) 3.41 (2.76-4.22) BUN >40 or Cr >2  
P=.005 P=.002 P<.001 P=.001 P<.001 
2.12 (1.41-3.18) 1.53 (1.10-2.12) 2.23 (1.39-3.57) 1.10 (0.72-1.68) 1.41 (1.24-1.59) Glucose <110 
P<.001 P=.012 P=.001 P=.648 P<.001 
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Table 7:  Adjusted 5-Year Cardiovascular, Stroke, & All-Cause Mortality 
ADJUSTED Hazard Ratios (95% Confidence Intervals) and P-Values 
Serum Values  
(mg/dL) 
AMI CAD (not AMI) CHF Stroke All Cause 
1.09 (0.70-1.71) 1.33 (0.91-1.92) 1.07 (0.63-1.81) 0.74 (0.46-1.18) 1.03 (0.90-1.18) HDL-C Female <50   
& Male <40  
P=.697 P=.137 P=.806 P=.204 P=.694 
0.68 (0.44-1.01) 1.18 (0.83-1.70) 0.53 (0.32-0.91) 0.96 (0.60-1.54) 1.08 (0.94-1.24) LDL <200 
P=.083 P=.359 P=.020 P=.867 P=.261 
0.63 (0.40-1.00) 1.35 (0.93-1.95) 1.35 (0.81-2.26) 0.73 (0.46-1.19) 1.19 (1.03-1.36) Triglycerides <150 
P=.049 P=.113 P=.253 P=.206 P=.017 
1.34 (0.65-2.77) 1.55 (0.83-2.90) 4.49 (2.40-8.38) 2.02 (0.94-4.33) 2.04 (1.63-2.54) BUN >40 or Cr >2  
P=.427 P=.167 P<.001 P=.071 P<.001 
1.83 (1.22-2.81) 1.29 (0.91-1.81) 1.63 (0.99-2.67) 1.00 (0.64-1.55) 1.22 (1.08-1.39) Glucose <110 
P=.004 P=.152 P=.053 P=.990 P=.002 
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An LDL-C of <200 mg/dL was significantly associated with increased 
crude all-cause (P<.001) and CAD (P=.018) mortality.  Following 
adjustment our covariates, the adjusted HR for CAD was no longer 
statistically significant (HR=1.18, 95% CI 0.83-1.70).   The LDL-C 
adjusted HR for decreased CHF mortality was now significant (p= 
.020, HR=0.53, 95% CI 0.32-0.91).  LDL-C and HDL-C were the only 
two serum values of interest that were not significantly associated 
with adjusted all-cause mortality.   
 
Impaired renal function indicated by a BUN >40 mg/dL or creatinine 
>2 mg/dL was significantly associated with crude all-cause (P<.001), 
AMI (P=.005), CAD (P=.002), CHF (P<.001), and stroke (P=.001) 
mortality.  Following adjustment our covariates, it remained 
significant with P<0.001 for both CHF (HR=4.49, 95% CI 2.40-8.38) 
and all-cause (HR=2.04, 95% CI 1.63-2.54) mortality.  The 
association between increased risk of CHF and all-cause mortality 
with impaired renal function is expected in light of the effect of renal 
function on CHF severity and its indication of overall poor health 
and comorbidity (96,97). 
 
Impaired glucose tolerance glucose indicated by a glucose value 
>110 mg/dL was significantly associated with crude all-cause 
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(P<.001), AMI (P<.001), CAD (P=.012), and CHF (P<.001) mortality.  
Following adjustment our covariates, it remained significant for both 
increased AMI (HR=1.85, 95% CI 1.22-2.81) and all-cause (HR=1.22, 
95% CI 1.08-1.39) mortality and very close to significant in CHF 
(p=.053) mortality.  Similarly, ideal triglyceride levels of <150 mg/dL 
were significantly associated with both unadjusted and adjusted 
AMI and all-cause mortality.  Likewise, the relationship between 
elevated glucose and AMI and all-cause mortality is unsurprising 
(98).   A similar relationship is also present with elevated 
triglycerides.  The mortality risks associated with elevated glucose 
and triglycerides could possibly related to the effects of metabolic 
syndrome in an older population (99), but documented fasting blood 
draws and waist-to-hip measurements are necessary to draw a 
conclusion between these factors since both these blood values are 
highly influences by the fasting vs.  non-fasting state.    
 
With respect to specific mortality outcomes, both CAD and stroke 
mortality lacked any significant association with any serum value.  
AMI was significantly associated with triglycerides and glucose, 
while BUN or creatinine was associated with CHF.  All three 
(triglycerides, glucose and BUN or creatinine) were significantly 
associated with all-cause mortality. 
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When examining the hazard ratios for all of our covariates, it 
becomes clear that factors beyond blood values are very important 
predictors of mortality (Figure 5).   Obviously, age, sex, and BMI are 
significant considerations, but gross mobility and basic functional 
status including performance of ADLs are also significant predictors 
of mortality.   
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Figure 5:  All Cause Mortality Hazard Ratios with 95% Confidence    
Intervals for Model Variables 
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CHAPTER 5:  DISCUSSION 
Laboratory research has taught us that HDL-C has a complex 
regulatory relationship to other plasma lipids and the vascular 
endothelium itself (4,13).  Epidemiological research has shown us 
the prospect of its use as a means of risk stratification (2,20-22).   It 
seems an obvious choice for mortality predictions, yet following 
adjustment for demographic, clinical, and functional covariates, 
there was no relationship between low HDL-C levels defined by 
current ATP III guidelines (<50 mg/dL in women and <40 mg/dL in 
men) and increased risk of 5-year cardiovascular, stroke or all-cause 
mortality among this cohort of older adults.  Even prior to full 
adjustment, the statistical significance of HDL-C levels stratified by 
current guidelines were not significantly predictive of cardiovascular 
or all-cause mortality with the exception of CAD (not AMI). This 
finding leaves us with several new questions with regard to 
appropriate lipid levels for risk stratification and guidelines for 
management of older adult patients.  We will examine the reason 
why HDL-C may lose predictive value in this cohort of older 
community-dwelling adults. We will also explore the unique 
characteristics of this cohort and extrapolate what our findings 
would mean for the patient presenting in clinic today. Lastly, we will 
look at the framework for future study of HDL-C in older adults. 
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Findings in primarily middle age cohorts have helped to define the 
current lipid profile guidelines, which we use as a yardstick for 
management in all our patients regardless of age.  In all areas of 
medicine, it is becoming more apparent that such epidemiologic 
study findings cannot be simply and broadly applied across both 
sexes and all age ranges. This may also ring true with regard to 
HDL-C level and older patients for several reasons. Since the elderly 
face competing mortality risks from co-morbidities and potential 
future illness, HDL-C alone may have minimal effect on future 
longevity (100).  Studies examining the lipid profiles in an elderly 
cohort of offspring of centenarians show a difference in lipid profiles 
with significantly decreased LDL levels and higher, but not 
significant HDL-C levels (101).  In light of this, numerous other 
environmental and genetic factors related to longevity may play a 
greater role either by affecting the ratio of anti-inflammatory to pro-
inflammatory HDL-C or by some other interaction with plasma 
lipids. Without dismissing the value of HDL-C in a middle-aged 
cohort, we should reconsider the role of HDL-C as a marker of the 
origination of arteriosclerosis and development of cardiovascular 
disease in a population set to have their initial event. In this context 
HDL-C would not necessarily exhibit a major predictive value in an 
older population with many other competing mortality risks.    
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Likewise, both acute and chronic systemic illness and inflammation, 
which may not always be recognized, can also play an important role 
in the progression of cardiovascular disease placing HDL-C in a 
setting where it may behave paradoxically to feed into this cycle 
rather than protect (4,11,14-17).  For example, higher-functioning 
and more-mobile older adults as represented by this study’s cohort 
typically have higher HDL-C levels, which are negatively correlated 
with visceral adiposity (suggestive of metabolic syndrome) compared 
to their non-community dwelling age-matched counterparts who 
have lower HDL-C levels showing no relationship to their waist girth 
(71,72).  Therefore, in choosing individuals capable of living 
independently, there is the inherent limitation of selecting those in 
better general health with potentially better though not necessarily 
“ideal” lipid profiles as compared to their institutionalized 
counterparts who are more likely affected by chronic illness.  
Through the selection of a more mobile cohort, we must accept that 
this sample does not represent all older adults, but does provide the 
benefit of representing the patient naïve to lipid-lowering 
medications who might walk into a clinician’s office where the 
decision point of whether or not to implement lipid therapy 
ultimately occurs. 
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In fact, a unique characteristic of this cohort is that they have not 
been treated with lipid-lowering therapies. It is likely that for this 
reason, the majority of this study’s cohort also has an elevated LDL 
≥200 mg/dL (60.9%). Today such a level will automatically warrant 
the use of a statin based on the ATP III guidelines to treat LDL-C 
≥100 mg/dL without even accounting for lower recommendations for 
that subset of patients with a prior history of cardiovascular disease 
(those with angina and/or previous MI) who would be treated if ≥70 
mg/dL.  For this reason, our study presents a somewhat artificial 
circumstance with regard to current treatment guidelines and goals. 
Even with this limitation, the lack of association found between LDL 
<200 mg/dL and all-cause, stroke and most cardiovascular 
outcomes presents an interesting question in itself. This lack of 
significance may be due to the choice of a high cut-off point going 
along with the evidence supporting current lower guidelines and 
with more recent evidence suggesting even more aggressive statin 
use to lower the LDL-C to around 70 mg/dL in those at greatest risk 
for cardiovascular events (2,75).   However, even with higher dose 
statin regimens, the decreased LDL-C achieved is only significantly 
related to the occurrence of new major cardiovascular event, but did 
not have any effect on overall mortality (75,77).  The effect of LDL-C 
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may be less dramatic when examined against longer term mortality 
and outside of the context of the various additional anti-
inflammatory benefits attributed to statin use, which was minimal 
(approximately 1%) within this study cohort (54). In one sense, the 
decision to treat a patient similar to our cohort to minimize 
morbidity related to cardiovascular disease may be clear with regard 
to their elevated LDL-C, but it is less clear on whether it is worth 
treating a low HDL-C, which would likely mean the use of multiple 
agents.  
 
Polypharmacy is a common situation and often a complaint in the 
elderly; thus, it is important that we consider this issue when 
making treatment decisions in this population. In addition to the 
sometimes complicated logistics and financial burden of taking 
multiple medications, there are the problems of drug interactions 
and paradoxical reactions related to impaired clearance due to 
changes in liver and renal function and differences in the volume 
distribution due to decreasing muscle mass. Yet, it is important to 
tread this slippery slope carefully because failure to prescribe a drug 
with potential morbidity and/or mortality benefits for cursory 
reasons is just as hazardous. To treat an increased LDL-C, patients 
regardless of age are often put on statin drugs, which do little to 
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affect HDL-C levels. Various studies have shown benefits of 
secondary prevention in adults over 65 years of age when treated 
with a statin including the prospective PROSPER, as well as 
subgroup analysis of older adults in CARE, 4S, and LIPID trials 
(102-105).  Unfortunately, data in the form of clinical trials 
regarding primary prevention in this population is notably lacking. 
Nonetheless, in the setting of a positive risk-benefit analysis, the 
evidence for treating an elevated LDL-C with a statin remains 
favorable in older adults without some other contraindication to 
therapy.  
 
If a physician chooses to treat a lower HDL-C level, the addition of a 
fibrate or niacin derivative would be the next course of action. No 
clinical trials focusing on the concurrent use of statins and fibrates 
have been done exclusively in an elderly population, but literature 
reviews of cohorts including these patients have shown no 
significant increased risks (106). However, increased age, female 
gender, renal or liver disease, diabetes, hypothyroidism, debilitated 
status, surgery, trauma, excessive alcohol intake, and heavy 
exercise increased risk for myopathy when these drug classes are 
used concurrently (106).  
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Clinical trials including older adults have also looked at statins and 
niacin for secondary prevention in cardiovascular disease looking at 
several measures. The ARBITER 2 trial had a primary outcome 
examining carotid intimal thickening in those with known 
cardiovascular disease following treatment with 1g of niacin in 
addition to a statin regimen (62).  Intimal thickening was 
significantly reduced in the dual treatment group and HDL-C levels 
were higher with no adverse events different from placebo (62).  Even 
though not in an exclusively elderly population, the mean age was 
67 years ±10 years.  Another study also showed an increase in HDL-
C on both drugs, but revealed no change in the plaque calcification 
or progression between statin and statin-niacin groups (107). So, 
HDL-C is elevated significantly with niacin though measurable 
effects on arteriosclerosis have not been found.  But, there also has 
not been an increase in side effects and extended release 
formulations have been better tolerated with regard to flushing, so 
the theoretical benefit comes with very little tangible risk. Just as 
with fibrates, there is a lack of clinical trials performed specifically in 
an older population. So, the clinician must extrapolate data from 
one population to another weighing risks and benefits obtained 
primarily from subgroups analysis and literature reviews in an effort 
to isolate adults over 65 years of age.    
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In the coming decades, we are facing a major shift that will affect the 
economics and practice of healthcare as we tackle the problems of 
an aging population.  We are also a society plagued by a deadly triad 
of obesity, diabetes, and cardiovascular disease, which only threaten 
to reach new heights. For these reasons, it is important to continue 
to refine the process of risk stratification and implement the 
appropriate interventions, pharmacologic or otherwise to decrease 
the morbidity and mortality associated with cardiovascular disease. 
To do this, medicine as a profession and to a great degree society 
itself has embraced evidence-based medical practice.  This has 
helped us create guidelines for practice that have in turn improved 
the delivery of the best known standard of care to greater numbers 
of patients.   
 
Our research aim was to test current guidelines and examine the 
relationship between untreated HDL-C levels below the 
recommended level of <50 mg/dL in women and <40 mg/dL in men 
on five year cardiovascular, stroke, and all-cause mortality in 
community-dwelling adults over 71 years of age.  Using these 
current recommended HDL-C levels clinically as a deciding factor for 
initiating aggressive lipid-lowering therapy in those without other 
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clear indications to reduce 5-year mortality is most likely not useful 
in those over 70 years of age.  However, there remain numerous 
gaps in the treatment of cardiovascular disease, which will need to 
be addressed in coming years.  These gaps will be filled in the 
laboratory to further explore the complex physiology of HDL-C and 
its interactions with other plasma lipids.  Likewise, they will need to 
be filled by clinical research focusing on those older adults who 
remain those with both the greatest risk and the potential for the 
greatest benefit. Until then, we must examine and re-examine those 
guidelines and goals we set to see if they do indeed match the 
patient sitting before us. In essence, that was the aim of this project 
and ultimately it is what physicians have always done--practice the 
art of medicine by utilizing careful clinical judgment in the face of 
what will always be limited evidence.  
72 
 
 
REFERENCES 
1. Thom T, Haase N, Rosamond W, et al. Heart Disease and 
Stroke Statistics--2006 Update: A Report From the American 
Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation 2006;113:e85-151. 
2. Executive Summary of the Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III). JAMA 
2001;285:2486-2497. 
3. Ettinger WH, Wahl PW, Kuller LH, et al. Lipoprotein lipids in 
older people. Results from the Cardiovascular Health Study. 
The CHS Collaborative Research Group. Circulation 
1992;86:858-69. 
4. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. 
High-Density Lipoprotein Function: Recent Advances. Journal 
of the American College of Cardiology 2005;46:1792. 
5. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM. 
Anti-Inflammatory Properties of HDL. Reviews in Endocrine & 
Metabolic Disorders 2004;5:351. 
6. Asztalos BF, Schaefer EJ. High-density lipoprotein 
subpopulations in pathologic conditions. Am J Cardiol 
2003;91:12E-17E. 
7. Figure 1: High Density Lipoprotein. Online Image. Feb. 2006. 
<http://www.icb.ufmg.br/pat/imagem/esquema/hdl.jpg>. 
73 
 
 
8. Nofer J-R, Kehrel B, Fobker M, Levkau B, Assmann G, 
Eckardstein Av. HDL and arteriosclerosis: beyond reverse 
cholesterol transport. Atherosclerosis 2002;161:1. 
9. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the Vascular 
Protective Effects of High-Density Lipoprotein and Its 
Apolipoproteins: An Idea Whose Time for Testing Is Coming, 
Part I. Circulation 2001;104:2376-2383. 
10. Tall AR. An overview of reverse cholesterol transport. 
European Heart Journal 1998;19. 
11. Ansell BJ, Navab M, Hama S, et al. 
Inflammatory/Antiinflammatory Properties of High-Density 
Lipoprotein Distinguish Patients from Control Subjects Better 
Than High-Density Lipoprotein Cholesterol Levels and Are 
Favorably Affected by Simvastatin Treatment. Circulation 
2003;108:2751. 
12. Kovanen PT, Pentikäinen MO. Circulating lipoproteins as 
proinflammatory and anti-inflammatory particles in 
atherogenesis. Current Opinion in Lipidology 2003;14:411. 
13. Watson AD, Berliner JA, Hama SY, et al. Protective effect of 
high density lipoprotein associated paraoxonase. Inhibition of 
the biological activity of minimally oxidized low density 
lipoprotein. Journal of Clinical Investigation 1995;96:2882. 
 
 
74 
 
 
14. Macdonald DL, Terry TL, Francis GA, Agellon LB, Nation PN. 
Administration of tyrosyl radical-oxidized HDL inhibits the 
development of atherosclerosis in apolipoprotein E-deficient 
mice. Arteriosclerosis, Thrombosis, and Vascular Biology 
2003;23:1583. 
15. Memon RA, Noor M, Moser AH, et al. Infection and 
inflammation induce LDL oxidation in vivo. Arteriosclerosis, 
Thrombosis, and Vascular Biology 2000;20:1536. 
16. Van Leeuwen HJ, Heezius ECJM, Van Strijp JAG, Verhoef J, 
Van Kessel KPM, Dallinga GM. Lipoprotein metabolism in 
patients with severe sepsis. Critical Care Medicine 
2003;31:1359. 
17. Van Lenten BJ, Wagner AC, Hama S, Navab M, Fogelman AM, 
Nayak DP. High-density lipoprotein loses its anti-inflammatory 
properties during acute influenza A infection. Circulation 
2001;103:2283. 
18. Navab M, Ananthramaiah GM, Reddy ST, et al. The double 
jeopardy of HDL. Ann Med 2005;37:173-8. 
19. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in 
human plasma. II. In atherosclerosis and related conditions. 
Am J Med 1951;11:480-93. 
20. Asztalos BF, Schaefer EJ. HDL in atherosclerosis: actor or 
bystander? Atheroscler Suppl 2003;4:21-9. 
21. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density 
lipoprotein cholesterol and cardiovascular disease. Four 
prospective American studies. Circulation 1989;79:8. 
75 
 
 
22. Boden WE. High-density lipoprotein cholesterol as an 
independent risk factor in cardiovascular disease: assessing 
the data from Framingham to the Veterans Affairs High--
Density Lipoprotein Intervention Trial. Am J Cardiol 
2000;86:19L-22L. 
23. Kannel WB, Dawber TR, McNamara PM. Detection of the 
coronary-prone adult: the Framingham study. J Iowa Med Soc 
1966;56:26-34. 
24. Assmann G, Schulte H. The Prospective Cardiovascular 
Munster Study: prevalence and prognostic significance of 
hyperlipidemia in men with systemic hypertension. Am J 
Cardiol 1987;59:9G-17G. 
25. Hulley S, Ashman P, Kuller L, Lasser N, Sherwin R. HDL-
cholesterol levels in the Multiple Risk Factor Intervention Trial 
(MRFIT) by the MRFIT Research Group 1,2. Lipids 
1979;14:119-123. 
26. The multiple risk factor intervention trial (MRFIT). A national 
study of primary prevention of coronary heart disease. Jama 
1976;235:825-7. 
27. Assmann G, Schulte H. Relation of high-density lipoprotein 
cholesterol and triglycerides to incidence of atherosclerotic 
coronary artery disease (the PROCAM experience). Prospective 
Cardiovascular Munster study. Am J Cardiol 1992;70:733-7. 
28. Assmann G, Funke H. HDL metabolism and atherosclerosis. J 
Cardiovasc Pharmacol 1990;16 Suppl 9:S15-20. 
76 
 
 
29. Dawber TR, Kannel WB. The Framingham study. An 
epidemiological approach to coronary heart disease. 
Circulation 1966;34:553-5. 
30. Thomas HE, Jr., Kannel WB, Dawber TR, McNamara PM. 
Cholesterol-phospholipid ratio in the prediction of coronary 
heart disease. The Framingham study. N Engl J Med 
1966;274:701-5. 
31. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum 
cholesterol, lipoproteins, and the risk of coronary heart 
disease. The Framingham study. Ann Intern Med 1971;74:1-
12. 
32. Kannel WB, Castelli WP, McNamara PM. Serum lipid fractions 
and risk of coronary heart disease. The Framingham study. 
Minn Med 1969;52:1225-30. 
33. Kannel WB, McGee D, Gordon T. A general cardiovascular risk 
profile: The Framingham study. The American Journal of 
Cardiology 1976;38:46. 
34. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to 
calculate the global risk of coronary heart disease: a 
systematic review of tools for clinicians. J Gen Intern Med 
2003;18:1039-52. 
35. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. 
High density lipoprotein as a protective factor against 
coronary heart disease: The Framingham study. The American 
Journal of Medicine 1977;62:707. 
 
77 
 
 
36. Kannel WB, Castelli WP, Gordon T. Cholesterol in the 
Prediction of Atherosclerotic Disease. Annals of Internal 
Medicine 1979;90:85. 
37. Castelli WP. Lipids, risk factors and ischaemic heart disease. 
Atherosclerosis 1996;124:S1. 
38. Laaksonen DE, Lakka H-M, Niskanen LK, Kaplan GA, Salonen 
JT, Lakka TA. Metabolic Syndrome and Development of 
Diabetes Mellitus: Application and Validation of Recently 
Suggested Definitions of the Metabolic Syndrome in a 
Prospective Cohort Study. Am. J. Epidemiol. 2002;156:1070-
1077. 
39. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction 
of coronary disease. Am Heart J 1992;124:768-74. 
40. Crow RS, Rautaharju PM, Prineas RJ, et al. Risk factors, 
exercise fitness and electrocardiographic response to exercise 
in 12,866 men at high risk of symptomatic coronary heart 
disease. Am J Cardiol 1986;57:1075-82. 
41. Relationship between baseline risk factors and coronary heart 
disease and total mortality in the multiple risk factor 
intervention trial. Preventive Medicine 1986;15:254. 
42. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density 
lipoprotein cholesterol and cardiovascular disease. Four 
prospective American studies. Circulation 1989;79:8-15. 
 
78 
 
 
43. Eberly LE, Prineas R, Cohen JD, et al. Metabolic Syndrome: 
Risk factor distribution and 18-year mortality in the Multiple 
Risk Factor Intervention Trial. Diabetes Care 2006;29:123-
130. 
44. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-
density lipoprotein cholesterol as a predictor of coronary heart 
disease risk. The PROCAM experience and pathophysiological 
implications for reverse cholesterol transport. Atherosclerosis 
1996;124:S11. 
45. Cornoni-Huntley J, Ostfeld AM, Taylor JO, et al. Established 
populations for epidemiologic studies of the elderly: study 
design and methodology. Aging (Milano) 1993;5:27-37. 
46. Mendes de Leon CF, Krumholz HM, Seeman TS, et al. 
Depression and risk of coronary heart disease in elderly men 
and women: New Haven EPESE, 1982-1991. Established 
Populations for the Epidemiologic Studies of the Elderly. Arch 
Intern Med 1998;158:2341-8. 
47. Schoenfeld DE, Malmrose LC, Blazer DG, Gold DT, Seeman 
TE. Self-rated health and mortality in the high-functioning 
elderly--a closer look at healthy individuals: MacArthur field 
study of successful aging. J Gerontol 1994;49:M109-15. 
48. Berkman LF, Seeman TE, Albert M, et al. High, usual and 
impaired functioning in community-dwelling older men and 
women: findings from the MacArthur Foundation Research 
Network on Successful Aging. J Clin Epidemiol 1993;46:1129-
40. 
79 
 
 
49. Feil D, Marmon T, Unutzer J. Cognitive impairment, chronic 
medical illness, and risk of mortality in an elderly cohort. Am 
J Geriatr Psychiatry 2003;11:551-60. 
50. Melzer D, Lan TY, Guralnik JM. The predictive validity for 
mortality of the index of mobility-related limitation--results 
from the EPESE study. Age Ageing 2003;32:619-25. 
51. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns 
of functional decline at the end of life. Jama 2003;289:2387-
92. 
52. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of 
association between cholesterol and coronary heart disease 
mortality and morbidity and all-cause mortality in persons 
older than 70 years. Jama 1994;272:1335-40. 
53. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol 
predicts coronary heart disease mortality in older persons. 
Jama 1995;274:539-44. 
54. Volpato S, Leveille SG, Corti M-C, Harris TB, Guralnik JM. 
The Value of Serum Albumin and High-Density Lipoprotein 
Cholesterol in Defining Mortality Risk in Older Persons with 
Low Serum Cholesterol. Journal of the American Geriatrics 
Society 2001;49:1142-1147. 
55. Rosenson RS. Low HDL-C: A secondary target of dyslipidemia 
therapy. The American Journal of Medicine 2005;118:1067. 
 
80 
 
 
56. Criqui MH, Wallace RB, Heiss G, Mishkel M, Schonfeld G, 
Jones GT. Cigarette smoking and plasma high-density 
lipoprotein cholesterol. The Lipid Research Clinics Program 
Prevalence Study. Circulation 1980;62:IV70. 
57. Belalcazar LM, Ballantyne CM. Defining specific goals of 
therapy in treating dyslipidemia in the patient with low high-
density lipoprotein cholesterol. Progress in Cardiovascular 
Diseases 1998;41:151. 
58. Glueck CJ, Taylor HL, Jacobs D, Morrison JA, Beaglehole R, 
Williams OD. Plasma high-density lipoprotein cholesterol: 
association with measurements of body mass. The Lipid 
Research Clinics Program Prevalence Study. Circulation 
1980;62:IV-62-9. 
59. Gordon DJ, Witztum JL, Hunninghake D, Gates S, Glueck CJ. 
Habitual physical activity and high-density lipoprotein 
cholesterol in men with primary hypercholesterolemia. The 
Lipid Research Clinics Coronary Primary Prevention Trial. 
Circulation 1983;67:512. 
60. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the 
amount and intensity of exercise on plasma lipoproteins. The 
New England Journal Of Medicine 2002;347:1483. 
61. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on 
blood lipids and lipoproteins: a meta-analysis. The American 
Journal Of Clinical Nutrition 1992;56:320. 
 
81 
 
 
62. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial 
Biology for the Investigation of the Treatment Effects of 
Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-
Controlled Study of Extended-Release Niacin on 
Atherosclerosis Progression in Secondary Prevention Patients 
Treated With Statins. Circulation 2004;110:3512-3517. 
63. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, 
antioxidant vitamins, or the combination for the prevention of 
coronary disease. The New England Journal Of Medicine 
2001;345:1583. 
64. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the 
secondary prevention of coronary heart disease in men with 
low levels of high-density lipoprotein cholesterol. Veterans 
Affairs High-Density Lipoprotein Cholesterol Intervention Trial 
Study Group. The New England Journal Of Medicine 
1999;341:410. 
65. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the 
Secondary Prevention of Coronary Heart Disease in Men with 
Low Levels of High-Density Lipoprotein Cholesterol. N Engl J 
Med 1999;341:410-418. 
66. Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and 
cardiovascular events with low HDL cholesterol: the Veterans 
Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 
2003;26:1513-7. 
 
82 
 
 
67. Secondary prevention by raising HDL cholesterol and reducing 
triglycerides in patients with coronary artery disease: the 
Bezafibrate Infarction Prevention (BIP) study. Circulation 
2000;102:21-7. 
68. Miller M. Differentiating the effects of raising low levels of 
high-density lipoprotein cholesterol versus lowering normal 
triglycerides: further insights from the Veterans Affairs High-
Density Lipoprotein Intervention Trial. Am J Cardiol 
2000;86:23L-27L. 
69. Goldenberg I, Goldbourt U, Boyko V, Behar S, Reicher-Reiss 
H. Relation Between On-Treatment Increments in Serum 
High-Density Lipoprotein Cholesterol Levels and Cardiac 
Mortality in Patients With Coronary Heart Disease (from the 
Bezafibrate Infarction Prevention Trial). Am J Cardiol 
2006;97:466-71. 
70. Gotto AM, Jr., Whitney E, Stein EA, et al. Relation Between 
Baseline and On-Treatment Lipid Parameters and First Acute 
Major Coronary Events in the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 
Circulation 2000;101:477-484. 
71. Zuliani G, Palmieri E, Volpato S, et al. High-density 
lipoprotein cholesterol strongly discriminates between healthy 
free-living and disabled octo-nonagenarians: a cross sectional 
study. Associazione Medica Sabin. Aging (Milano) 1997;9:335-
41. 
 
83 
 
 
72. Zuliani G, Romagnoni F, Bollini C, Leoci V, Soattin L, Fellin R. 
Low levels of high-density lipoprotein cholesterol are a marker 
of disability in the elderly. Gerontology 1999;45:317-22. 
73. U.S. Census Bureau. Census 2000 Brief: The 65 Years and 
Over Population. 2000. 
74. U.S. Census Bureau. 2000 Population  Press Release on 65+. 
2000. 
75. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid 
lowering with atorvastatin in patients with stable coronary 
disease. N Engl J Med 2005;352:1425-35. 
76. Aronow WS. Don't trust an LDL over 70? Geriatrics 2004;59:12-3. 
77. Pitt B. Low-density lipoprotein cholesterol in patients with 
stable coronary heart disease--is it time to shift our goals? N 
Engl J Med 2005;352:1483-4. 
78. Anum EA, Adera T. Hypercholesterolemia and coronary heart 
disease in the elderly: a meta-analysis. Ann Epidemiol 
2004;14:705-21. 
79. Kronmal RA, Kosinski AS, Mock MB. The relationship between 
cholesterol level and myocardial infarction or mortality risk in 
patients with coronary artery disease. A report from the 
Coronary Artery Surgery Study (CASS) registry. Ann Epidemiol 
1992;2:129-36. 
80. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux 
R. Relationship between plasma lipids and all-cause mortality 
in nondemented elderly. J Am Geriatr Soc 2005;53:219-26. 
84 
 
 
81. Chyou PH, Eaker ED. Serum cholesterol concentrations and 
all-cause mortality in older people. Age & Ageing 2000;29:69-
74. 
82. Asia Pacific Cohort Studies C. A Comparison of Lipid Variables 
as Predictors of Cardiovascular Disease in the Asia Pacific 
Region. Annals of Epidemiology 2005;15:405. 
83. Thompson MM, Reed SC, Cockerill GW. Therapeutic 
approaches to raising plasma HDL-cholesterol levels. Nat Clin 
Pract Cardiovasc Med 2004;1:84-9. 
84. Blood pressure studies in 14 communities. A two-stage screen 
for hypertension. Jama 1977;237:2385-91. 
85. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. 
Studies Of Illness In The Aged. The Index Of Adl: A 
Standardized Measure Of Biological And Psychosocial 
Function. Jama 1963;185:914-9. 
86. Rosow I, Breslau N. A Guttman health scale for the aged. J 
Gerontol 1966;21:556-9. 
87. Nagi SZ. An epidemiology of disability among adults in the 
United States. Milbank Mem Fund Q Health Soc 1976;54:439-
67. 
88. Pfeiffer E. A short portable mental status questionnaire for the 
assessment of organic brain deficit in elderly patients. J Am 
Geriatr Soc 1975;23:433-41. 
 
85 
 
 
89. Karlamangla AS, Singer BH, Reuben DB, Seeman TE. 
Increases in serum non-high-density lipoprotein cholesterol 
may be beneficial in some high-functioning older adults: 
MacArthur studies of successful aging. J Am Geriatr Soc 
2004;52:487-94. 
90. Ettinger WH, Jr., Verdery RB, Wahl PW, Fried LP. High 
density lipoprotein cholesterol subfractions in older people. J 
Gerontol 1994;49:M116-22. 
91. Craig SR, Amin RV, Russell DW, Paradise NF. Blood 
cholesterol screening influence of fasting state on cholesterol 
results and management decisions. J Gen Intern Med 
2000;15:395-9. 
92. ICD-9-CM. Official authorized addendum for the International 
Classification of Diseases, Ninth Revision, Clinical 
Modification. Volumes 1, 2, and 3. Effective for discharge 
October 1, 1988. National Center for Health Statistics and the 
Health Care Financing Administration. J Am Med Rec Assoc 
1988;59:suppl 1-34. 
93. Smith CJ, Scott SM, Wagner BM. The necessary role of the 
autopsy in cardiovascular epidemiology. Hum Pathol 
1998;29:1469-79. 
94. Lakkireddy DR, Gowda MS, Murray CW, Basarakodu KR, 
Vacek JL. Death certificate completion: how well are 
physicians trained and are cardiovascular causes overstated? 
Am J Med 2004;117:492-8. 
86 
 
 
95. Breslow N. Covariance analysis of censored survival data. 
Biometrics 1974;30:89-99. 
96. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and 
impact on outcomes of worsening renal function in patients > 
or =65 years of age with heart failure. Am J Cardiol 
2000;85:1110-3. 
97. Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease 
risk status in elderly persons with renal insufficiency. Kidney 
Int 2002;62:997-1004. 
98. Hoogwerf BJ, Sprecher DL, Pearce GL, et al. Blood glucose 
concentrations < or = 125 mg/dl and coronary heart disease 
risk. Am J Cardiol 2002;89:596-9. 
99. Lindberg O, Tilvis RS, Strandberg TE, et al. Impacts of 
components of the metabolic syndrome on health status and 
survival in an aged population. Eur J Epidemiol 1997;13:429-
34. 
100. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. 
Estimating Treatment Benefits for the Elderly: The Effect of 
Competing Risks. Ann Intern Med 1996;124:577-584. 
101. Barzilai N, Gabriely I, Gabriely M, Iankowitz N, Sorkin JD. 
Offspring of centenarians have a favorable lipid profile. J Am 
Geriatr Soc 2001;49:76-9. 
102. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering 
therapy in women and elderly patients with myocardial 
infarction or angina pectoris: findings from the Scandinavian 
Simvastatin Survival Study (4S). Circulation 1997;96:4211-8. 
87 
 
 
103. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on 
cardiovascular events in older patients with myocardial 
infarction and cholesterol levels in the average range. Results 
of the Cholesterol and Recurrent Events (CARE) trial. Ann 
Intern Med 1998;129:681-9. 
104. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on 
cardiovascular events and mortality in older patients with 
coronary heart disease are equal to or exceed those seen in 
younger patients: Results from the LIPID trial. Ann Intern Med 
2001;134:931-40. 
105. Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins 
and apolipoproteins as predictors of cardiovascular risk and 
treatment benefit in the PROspective Study of Pravastatin in 
the Elderly at Risk (PROSPER). Circulation 2005;112:3058-65. 
106. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann 
Pharmacother 2001;35:908-17. 
107. Hecht HS, Harman SM. Comparison of effectiveness of statin 
monotherapy versus statin and niacin combination therapy in 
primary prevention and effects on calcified plaque burden. Am 
J Cardiol 2003;91:348-51. 
 
 
88 
 
 
APPENDIX 1:  EPESE Questions for Variables  
DEMOGRAPHIC VARIABLES 
Sex:  1.6   Sex  1 = Male       2 = Female   
 
Race:  1.7   Race (Not East Boston)         
1 = White                                                                           
2 = Black 
3 = Other 
 Blank  
 
Age:  2.2   Calculated age at time of interview       Years 
 
Education:          2.17    What is the highest grade or year of     Year  
                             regular school you have completed?   
 
Marital Status: 2.18     Have you ever been married?    
              1 = Yes      2 = No 
 
 2.19     Are you now married,         1 = Married  
 separated, divorced or widowed?    2 = Separated 
 Are you now married, widowed,      3 = Divorced   
 divorced or separated?                    4 = Widowed 
                                  5 = Annulled     
     
CLINICAL VARIABLES 
Cancer History:  29.18   Has a doctor ever told you that you   1=Yes  
had a cancer, malignancy or malignant         2=Suspect 
tumor of any type?            3=no 
 
Diabetes History:  29.41 Has a doctor ever told you that you     1=Yes  
had diabetes, high blood sugar, or sugar      2=Suspect 
in your urine?           3=No 
 
Antihypertensive: 29.60 Are you currently taking any          1=Yes 
medications for your high blood pressure?     2=No 
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Angina:   34.18 Do you get this pain when you hurry         1=Yes 
    or walk uphill?                   2=No 
                                                                                   3=Never walks uphill 
 
Myocardial   29.1 Have you ever been told by a doctor      1=Yes 
Infarction :  that you had a heart atttack, coronary,         2=Suspect 
coronary thrombosis, coronary occlusion,     3=No 
or myocardial infarction?      
 
FUNCTIONAL VARIABLES 
 
Cognitive Status: (Short Portable Mental Status Questionnaire) 
19.1     How old are you? 1 = Correct     2 = Incorrect  
19.2  When were you born? 1 = Correct     2 = Incorrect  
19.3  What is the date today? 1 = Correct     2 = Incorrect 
3 = Correct with aid (EBoston) 
  
19.4      What day of the week is it? 1 = Correct     2 = Incorrect  
  3 = Correct with aid (EBoston) 
  
19.5 Who is the president of the U.S. 1 = Correct     2 = Incorrect  
 (now)? 3 = Correct with aid (EBoston)  
 
19.6 Who was (the) president (just)  1 = Correct     2 = Incorrect  
  before  him?       3 = Correct with aid (EBoston) 
  
19.7      What was (is) your mother's 1 = Correct     2 = Incorrect 
 maiden name? 3 = Correct with aid (EBoston) 
  
19.8      What is your telephone number? 1 = Correct     2 = Incorrect 
3 = Correct with aid (EBoston) 
  4 = No telephone (NHaven & EBoston) 
 
19.9      What is your (street) address? 1 = Correct       2 = Incorrect 
               3 = Correct with aid (EBoston) 
90 
 
 
Gross Mobility:  
20.32  Are you able to do heavy work around the     1 = Yes  
            house like (shoveling snow), washing                        2 = No  
windows, walls or floors without help   
(from another person)? 
 
20.33  Are you able to walk up and down stairs                     1 = Yes  
to the second floor without help (from                         2 = No  
another person)?    
 
20.34 Are you able to walk half a mile without                      1 = Yes  
help (from another person)?  That's about                   2 = No  
8 ordinary blocks.   
 
Physical Performance Difficulties 
 
20.39     How much difficulty, if any, do you have      1 = No difficulty at all  
 pulling or pushing large objects like a         2 = little/some difficulty 
 living room chair?            3 = A lot of difficulty  
                                                                               4 = Just unable to do it 
 
20.40     What about stooping, crouching, or          1 = No difficulty at all 
           kneeling?                                                    2 = little/some difficulty 
             3 = A lot of difficulty  
                                                                              4 = Just unable to do it  
 
20.43     Reaching or extending arms above           1 = No difficulty at all 
           shoulder level?           2 = little/some difficulty   
                                                                  3 = A lot of difficulty  
                                                                              4 = Just unable to do it  
 
20.44     Either writing or handling (or                   1 = No difficulty at all            
fingering) small objects?           2 = little/some difficulty 
           3 = A lot of difficulty  
                                                                              4 = Just unable to do it   
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APPENDIX 2: EPESE Blood Values  
East Boston (N=1248) Iowa (N=1939) New Haven (N=997) Total (N=4184) Laboratory Tests 
n Mean (±SD) n Mean (±SD) N Mean (±SD) n Mean 
WBC 1152 7.0 (±2.2) 1928 6.4 (±2.6) 866 6.7 (±2.7) 3946 6.7 
RBC 1152 4.4 (±0.5) 1928 4.6 (±0.5) 866 4.5 (±0.5) 3946 4.5 
HEMOGLOBIN 1152 13.4 (±1.5) 1928 14.2 (±1.5) 866 13.4 (±1.6) 3946 13.7 
HEMATOCRIT 1152 40.5 (±4.4) 1928 42.7 (±4.4) 866 40.9 (±4.8) 3946 41.4 
MCV 1152 91.5 (±6.5) 1928 93.7 (±5.3) 866 92.1 (±6.0) 3946 92.4 
MCH  1152 30.3 (±2.4) 1928 31.1 (±1.9) 866 30.2 (±2.2) 3946 30.5 
MCHC 1152 33.1 (±0.7) 1928 33.2 (±0.8) 866 32.8 (±0.9) 3946 33.0 
RBC WIDTH 1152 14.4 (±1.7) 1550 15.0 (±1.9) 866 15.1 (±2.0) 3568 14.9 
PLATELETS 1102 255.3 (±75.6) 1901 251.2 (±89.7) 840 269.1(±87.2) 3843 258.5 
NEUTROPHILS 1102 60.3 (±10.6) 1707 63.2 (±9.6) 811 61.7 (±10.1) 3620 61.7 
BANDS 973 0.4 (±1.0) 1387 0.2 (±0.8) 660 0.2 (±0.7) 3020 0.3 
LYMPHOCYTES 1102 33.8 (±10.5) 1707 32.5 (±9.5) 811 33.8 (±9.9) 3620 33.3 
MONOCYTES 1088 3.2 (±2.2) 1652 2.5 (±2.1) 795 2.5 (±2.5) 3535 2.7 
EOSINOPHILS 1058 2.0 (±2.0) 1651 1.7 (±1.7) 777 1.9 (±2.1) 3486 1.9 
BASOPHILS 965 0.3 (±0.6) 1414 0.2 (±0.5) 671 0.2 (±0.4) 3050 0.2 
GLUCOSE 1212 133.3 (±61.9) 1932 119.6 (±49.1) 975 124.0 (±56.1) 4119 125.6 
BUN 1212 20.4 (±7.8) 1932 19.7 (±7.3) 975 20.5 (±8.6) 4119 20.2 
CREATININE 1212 1.4 (±4.3) 1932 1.2 (±0.4) 975 1.3 (±1.0) 4119 1.3 
URIC ACID 1212 6.2 (±2.0) 1932 6.3 (±1.7) 974 6.4 (±1.7) 4118 6.3 
SODIUM 1212 139.2 (±7.0) 1932 140.5 (±4.5) 974 139.7 (±5.4) 4118 139.8 
POTASSIUM 1212 4.3 (±0.5) 1932 4.7 (±0.6) 974 4.4 (±0.6) 4118 4.5 
CHLORIDE 1212 101.8 (±6.2) 1932 102.7 (±4.6) 974 101.5 (±5.4) 4118 102.0 
BICARBONATE 1211 28.2 (±4.5) 1932 29.8 (±4.6) 975 34.9 (±6.9) 4118 31.0 
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East Boston (N=1248) Iowa (N=1939) New Haven (N=997) Total (N=4184) Laboratory Tests 
n Mean (±SD) n Mean (±SD) N Mean (±SD) n Mean 
TOTAL PROTEIN 1212 7.1 (±6.0) 1932 6.8 (±0.5) 975 6.9 (±0.7) 4119 6.9 
ALBUMIN 1211 4.1 (±1.0) 1932 4.1 (±0.3) 975 4.0 (±0.3) 4118 4.1 
CALCIUM 1211 9.5 (±0.7) 1932 9.5 (±0.5) 975 9.5 (±1.4) 4118 9.5 
PHOSPHATE 1211 3.7 (±3.9) 1932 3.6 (±0.5) 975 3.5 (±0.5) 4118 3.6 
LDH 1210 156.9 (±48.2) 1932 175.6 (±40.2) 975 162.7 (±43.0) 4117 165.1 
SGOT 1210 16.6 (±13.5) 1931 17.4 (±9.6) 975 16.4 (±18.5) 4116 16.8 
GGT 1211 26.8 (±36.0) 1932 24.2 (±41.7) 975 25.8 (±33.4) 4118 25.6 
ALKALINE PHOSPHATASE 1211 101.8 (±72.0) 1932 98.1 (±53.0) 975 118.5 (±229.0) 4118 106.1 
TOTAL BILIRUBIN 1211 0.4 (±0.3) 1932 0.4 (±0.2) 975 0.4 (±0.3) 4118 0.4 
CHOLESTEROL (SMA) 1211 216.0 (±42.9) 1932 217.4 (±42.1) 975 213.7 (±43.7) 4118 215.7 
TRIGLYCERIDES 1211 184.5 (±110.9) 1931 179.8 (±117.7) 975 171.0 (±111.3) 4117 178.4 
IRON 1211 79.5 (±29.3) 1932 85.8 (±29.8) 974 76.0 (±28.6) 4117 80.4 
GLOBULIN 1211 3.1 (±8.3) 1932 2.7 (±0.4) 975 2.9 (±1.1) 4118 2.9 
ALBUMIN/GLOBULIN 
RATIO 1211 1.5 (±1.4) 1932 1.5 (±0.3) 974 1.5 (±0.3) 4117 1.5 
BUN/CREATININE RATIO 1209 17.4 (±4.8) 1932 16.6 (±4.9) 974 17.0 (±5.7) 4115 17.0 
CHOLESTEROL 1216 214.0 (±42.8) 1934 215.8 (±44.0) 983 214.9 (±44.1) 4133 214.9 
HDL CHOLESTEROL 1215 46.5 (±14.8) 1934 49.3 (±14.7) 979 48.5 (±14.7) 4128 48.1 
DHEAS 1225 0.5 (±0.4) nc nc Nc nc 1225 0.5 
HEMOGLOBIN A1C 1221 6.3 (±1.3) 1698 5.7 (±1.2) Nc nc 2919 6.0 
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APPENDIX 3:  Chi-Square Best-Fit Modeling 
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                 5-Year Stroke Mortality Best Fit Modeling Data
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Best Subset (p=0.05) 5-year All Cause Mortality Cox proportional Hazards Regression Model 
 
The PHREG Procedure  
 
Regression Models Selected by Score Criterion  
 
# of 
Variables 
Score  
Chi-Square  
Variables Included in Model  
1  424.8006  GrossMobilityBase_6  
1  299.0994  age_6  
1  178.1457  BUN_Gr_40_OR_Creat_Gr_2  
   
2  603.8073  GrossMobilityBase_6 Female  
2  559.1845  GrossMobilityBase_6 BUN_Gr_40_OR_Creat_Gr_2  
2  537.9685  GrossMobilityBase_6 age_6  
   
3  728.1566  GrossMobilityBase_6 Female age_6  
3  715.6414  GrossMobilityBase_6 Female BUN_Gr_40_OR_Creat_Gr_2  
3  666.3973  GrossMobilityBase_6 age_6 BUN_Gr_40_OR_Creat_Gr_2  
   
4  833.6088  GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
4  763.4625  ADLscorebase_6 GrossMobilityBase_6 Female age_6  
4  754.0138  pulse_10 GrossMobilityBase_6 Female BUN_Gr_40_OR_Creat_Gr_2  
   
5  870.1502  ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
5  852.2660  pulse_10 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
5  847.9079  BP_D_Ls_90_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
   
6  888.8593  pulse_10 ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
6  884.8292  DM_score ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
6  881.5548  BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
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7  901.9492  DM_score pulse_10 ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
7  900.6105  HxAMI_score pulse_10 ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
7  899.7256  pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 BUN_Gr_40_OR_Creat_Gr_2  
   
8  913.3662  DM_score HxAMI_score pulse_10 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2  
8  913.1660  DM_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2  
8  911.9676  HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2  
   
9  925.0698  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2  
9  921.3095  HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Glucose_Gr_110  
9  920.4280  DM_score HxAMI_score pulse_10 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150  
   
10  932.2928  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150  
10  931.0943  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2  
10  930.9000  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Glucose_Gr_110  
   
11  940.1858  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
11  937.6540  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150  
11  937.5592  DM_score HxAMI_score Hx_Cu_Smoker_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150  
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12  946.1273  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
12  945.1906  DM_score HxAMI_score Hx_Cu_Smoker_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
12  943.9019  DM_score HxAMI_score HTN_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
13  951.5826  DM_score HxAMI_score Hx_Cu_Smoker_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
13  949.4635  DM_score HxAMI_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
13  949.4000 DM_score HxAMI_score HTN_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
14  955.2667  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
14  954.8939  DM_score HxAMI_score Hx_Cu_Smoker_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 White LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
14  954.7451  DM_score HxAMI_score Hx_Cu_Smoker_score ChxPain pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
15  958.4076  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
15  958.3946  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
15  958.3903  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
16  961.6841  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
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16  961.5998  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
16  961.4133  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110 
                   
17  964.7687  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
17  963.9444  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain pulse_10 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
17  963.8255  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
   
18  967.0233  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
18  966.7581  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
18  966.7377  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 GrossMobilityBase 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
19  969.0675  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
19  968.9717  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 pulse_10 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
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19  968.8946  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 GrossMobilityBase 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200, 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
20  971.0972  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 pulse_10 
GrossMobilityBase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
20  970.9692  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
20  970.8880  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score ChxPain BP_D_Ls_90 pulse_10 
GrossMobilityBase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
21  973.0380  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
21  972.8801  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
21  972.7716  DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 pulse_10 
GrossMobilityBase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
   
22  974.7774  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
22  974.7531  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
White Married LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
 
22  
 
974.6717  
 
DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
White Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
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23  976.6861  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
23 976.0371 DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 
White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
23 975.8508 DM_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 pulse_10 
GrossMobilityBase PPDscorebase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female 
age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
   
24  977.8364  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
24  977.3645  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
24  977.1638  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
Glucose_Gr_110  
   
25  978.5045  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
25  978.2845  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 Glucose_Gr_110  
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25  978.2538  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
   
26  978.9466  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
26  978.9069  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
26  978.7108  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 
GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
   
27  979.3576  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
27  979.0984 DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110  
 
27  
 
979.0589  
 
DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med ChxPain 
BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 Glucose_Gr_110 
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28  979.4963  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain 
BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
28  979.4564  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain BP_D_Ls_90 
pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 
ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 
BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
28  979.4476  DM_score Canx_score HxAMI_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med ChxPain 
BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
29  979.6016  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain 
BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F 
Glucose_Gr_110 
    
29  979.5784 DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
BP_Med ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase 
BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F 
Glucose_Gr_110  
29  979.5559  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
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30  979.6884  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F 
Glucose_Gr_110  
30  979.6634  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score ChxPain 
BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F 
Glucose_Gr_110  
30 979.6434 DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 Female age_6 White Married Edu_Ls_7_year 
LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
31  979.7559  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase BP_S_Gr_160_6 
BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 White Married 
Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F 
Glucose_Gr_110 
    
31  979.692
2 
DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
BP_Med ChxPain BP_S_Gr_160 BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase 
SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 
Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
 
31  
979.690
7 
DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
BP_Med ChxPain BP_D_Ls_90 pulse_10 ETOH_use ADLscorebase GrossMobilityBase PPDscorebase 
SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 
Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
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32 979.7588  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med 
ChxPain BP_D_Ls_90 pulse_10 ETOH_use ADLscorebase GrossMobilityBase PPDscorebase SPMSQscorebase 
BP_S_Gr_160_6 BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 
White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
32  979.7585  DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med 
ChxPain BP_S_Gr_160 BP_D_Ls_90 pulse_10 ETOH_use GrossMobilityBase PPDscorebase SPMSQscorebase 
BP_S_Gr_160_6 BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 PPDscorebase_6 Female age_6 
White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 Triglycerides_Ls_150 
HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
32  979.694
5  
DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score 
BP_Med ChxPain BP_S_Gr_160 BP_D_Ls_90 pulse_10 ETOH_use ADLscorebase GrossMobilityBase 
PPDscorebase SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 ADLscorebase_6 GrossMobilityBase_6 
PPDscorebase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110  
   
33  979.7613 DM_score Canx_score HxAMI_score DM_suspect_score Hx_Cu_Smoker_score HTN_score Obesity_score BP_Med  
ChxPain BP_S_Gr_160 BP_D_Ls_90 pulse_10 ETOH_use ADLscorebase GrossMobilityBase PPDscorebase 
SPMSQscorebase BP_S_Gr_160_6 BP_D_Ls_90_6 pulse_10_6 ADLscorebase_6 GrossMobilityBase_6 
PPDscorebase_6 Female age_6 White Married Edu_Ls_7_year LDL_Ls_200 BUN_Gr_40_OR_Creat_Gr_2 
Triglycerides_Ls_150 HDL_Ls_40_M_Ls_50_F Glucose_Gr_110 
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   APPENDIX 4:   Full Statistical Model Results 
5-Year AMI Mortality Cox proportional Hazards Regression Model w/Blood 
 
The PHREG Procedure  
Model Information  
 
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  AMI5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  107  4077  97.44  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                       Without                   With  
Criterion  Covariates     Covariates  
-2 LOG L  1755.888  1719.240  
AIC  1755.888  1729.240  
SBC  1755.888  1742.604  
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                                                          5-Year AMI Mortality Cox proportional Hazards Regression Model w/ Blood 
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  36.6476  5  <.0001  
Score  40.9020  5  <.0001  
Wald  37.5295  5  <.0001  
 
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio             Confidence Limits  
          LDL_Ls_200  1  0.08323  0.20777  0.1605  0.6887  1.087  0.723  1.633  
BUN_Gr_40_OR_Creat_Gr_2  1  0.99034  0.35274  7.8822  0.0050  2.692  1.348  5.375  
Triglycerides_Ls_150  1  -0.56033  0.22953  5.9594  0.0146  0.571  0.364  0.895  
HDL_Ls_40_M_Ls_50_F  1  0.15770  0.21972  0.5151  0.4729  1.171  0.761  1.801  
Glucose_Gr_110  1  0.75243  0.20701  13.2114  0.0003  2.122  1.414  3.184  
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5-Year AMI Mortality Cox proportional Hazards Regression Model w/ blood + demo 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  AMI5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
                                                                                             4184  107  4077  97.44  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied. 
 
Model Fit Statistics  
 
Without                With  
Criterion      Covariates     Covariates  
-2 LOG L  1755.888  1676.181  
AIC  1755.888  1696.181  
SBC  1755.888  1722.910  
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5-Year AMI Mortality Cox proportional Hazards Regression Model w/blood + demo 
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
                                                                           Likelihood Ratio  79.7063  10  <.0001  
Score  85.9212  10  <.0001  
Wald  79.4891  10  <.0001  
 
Analysis of Maximum Likelihood Estimates 
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
 
LDL_Ls_200  1  -0.26375  0.21562  1.4964  0.2212  0.768  0.503  1.172  
BUN_Gr_40_OR_Creat_Gr_2  1  0.67327  0.35841  3.5287  0.0603  1.961  0.971  3.958  
Triglycerides_Ls_150  1  -0.52683  0.22886  5.2989  0.0213  0.590  0.377  0.925  
HDL_Ls_40_M_Ls_50_F  1  0.27265  0.21929  1.5459  0.2137  1.313  0.855  2.019  
Glucose_Gr_110  1  0.72403  0.20713  12.2182  0.0005  2.063  1.374  3.096  
Female  1  -1.17961  0.22181  28.2826  <.0001  0.307  0.199  0.475  
age_6  1  0.06032  0.01681  12.8764  0.0003  1.062  1.028  1.098  
White  1  0.18919  0.21218  0.7951  0.3726  1.208  0.797  1.831  
Married  1  -0.11299  0.21869  0.2670  0.6054  0.893  0.582  1.371  
Edu_Ls_7_year  1  0.27123  0.24839  1.1924  0.2749  1.312  0.806  2.134  
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      5-Year AMI Mortality Cox proportional Hazards Regression Model  all together 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  AMI5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  107  4077  97.44  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
Without                 With  
Criterion     Covariates     Covariates  
-2 LOG L  1755.888  1613.378  
AIC  1755.888  1679.378  
SBC  1755.888  1767.581  
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5-Year AMI Mortality Cox proportional Hazards Regression Model all together  
 
The PHREG Procedure  
Testing Global Null Hypothesis: BETA=0  
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  142.5101  33  <.0001  
Score  156.9387  33  <.0001  
Wald  142.8223  33  <.0001  
 
Analysis  of Maximum  Likelihood Estimates  
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  -0.38116  0.21966  3.0109  0.0827  0.683  0.444  1.051  
BUN_Gr_40_OR_Creat_Gr_2  1  0.29402  0.37024  0.6306  0.4271  1.342  0.649  2.772  
Triglycerides_Ls_150  1  -0.45826  0.23313  3.8640  0.0493  0.632  0.400  0.999  
HDL_Ls_40_M_Ls_50_F  1  0.08859  0.22766  0.1514  0.6972  1.093  0.699  1.707  
Glucose_Gr_110  1  0.61348  0.21347  8.2589  0.0041  1.847  1.215  2.806  
Female  1  -1.36701  0.24123  32.1124  <.0001  0.255  0.159  0.409  
age_6  1  0.03336  0.01819  3.3627  0.0667  1.034  0.998  1.071  
White  1  0.24346  0.22987  1.1217  0.2896  1.276  0.813  2.002  
Married  1  -0.05046  0.22095  0.0522  0.8193  0.951  0.617  1.466  
Edu_Ls_7_year  1  0.30626  0.25307  1.4646  0.2262  1.358  0.827  2.231  
DM_score  1  0.10041  0.05318  3.5653  0.0590  1.106  0.996  1.227  
Canx_score  1  -0.15581  0.11236  1.9231  0.1655  0.856  0.687  1.067  
HxAMI_score  1  0.06329  0.07289  0.7540  0.3852  1.065  0.924  1.229  
DM_suspect_score  1  -0.83785  0.89361  0.8791  0.3485  0.433  0.075  2.493  
Hx_Cu_Smoker_score  1  0.16723  0.05950  7.8999  0.0049  1.182  1.052  1.328  
HTN_score  1  -0.03717  0.06097  0.3717  0.5421  0.964  0.855  1.086  
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Obesity_score  1  -0.02631  0.04081  0.4156  0.5191  0.974  0.899  1.055  
BP_Med  1  0.15727  0.21490  0.5356  0.4643  1.170  0.768  1.783  
ChxPain  1  0.71790  0.43675  2.7019  0.1002  2.050  0.871  4.826  
BP_S_Gr_160  1  0.19139  0.31361  0.3724  0.5417  1.211  0.655  2.239  
BP_D_Ls_90  1  -0.46577  0.25028  3.4635  0.0627  0.628  0.384  1.025  
pulse_10  1  0.06958  0.07645  0.8285  0.3627  1.072  0.923  1.245  
ETOH_use  1  -0.10842  0.21203  0.2614  0.6091  0.897  0.592  1.360  
ADLscorebase  1  -9.74559  519.14622  0.0004  0.9850  0.000  0.000  
GrossMobilityBase  1  -0.05434  0.12987  0.1751  0.6756  0.947  0.734  1.222  
PPDscorebase  1  0.13681  0.14102  0.9412  0.3320  1.147  0.870  1.512  
SPMSQscorebase  1  -0.04864  0.08329  0.3410  0.5592  0.953  0.809  1.121  
BP_S_Gr_160_6  1  -0.55703  0.39732  1.9655  0.1609  0.573  0.263  1.248  
BP_D_Ls_90_6  1  -0.56231  0.28271  3.9562  0.0467  0.570  0.327  0.992  
pulse_10_6  1  0.18052  0.07601  5.6406  0.0175  1.198  1.032  1.390  
ADLscorebase_6  1  -0.40808  0.68828  0.3515  0.5533  0.665  0.173  2.562  
GrossMobilityBase_6  1  -0.31718  0.10694  8.7967  0.0030  0.728  0.591  0.898  
PPDscorebase_6  1  -0.09209  0.12426  0.5492  0.4587  0.912  0.715  1.164  
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5-year CAD Mortality Cox proportional Hazards Regression Model  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  CAD5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
Percent  
Total  Event  Censored  Censored  
4184  149  4035  96.44  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
 
Model Fit Statistics  
 
                                                                                                                        Without                   With  
Criterion  Covariates  Covariates  
 
-2 LOG L  2444.961  2411.221  
AIC  2444.961  2421.221  
SBC  2444.961  2436.241  
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5-year CAD Mortality Cox proportional Hazards Regression Model w/ Blood 
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  33.7406  5  <.0001  
Score  39.7659  5  <.0001  
Wald  37.6758  5  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.40909  0.17256  5.6201  0.0178  1.505  1.073  2.111  
BUN_Gr_40_OR_Creat_Gr_2  1  0.96839  0.30539  10.0551  0.0015  2.634  1.447  4.792  
Triglycerides_Ls_150  1  0.31480  0.18300  2.9591  0.0854  1.370  0.957  1.961  
HDL_Ls_40_M_Ls_50_F  1  0.39384  0.18507  4.5288  0.0333  1.483  1.032  2.131  
Glucose_Gr_110  1  0.42185  0.16837  6.2775  0.0122  1.525  1.096  2.121  
 
 
 
 
 
 
 
 
 
   
 
115 
5-year CAD Mortality Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  CAD5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  149  4035  96.44  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                        Without                  With  
Criterion  Covariates  Covariates  
-2 LOG L  2444.961  2349.452  
AIC  2444.961  2369.452  
SBC  2444.961  2399.491  
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5-year CAD Mortality Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  95.5096  10  <.0001  
Score  116.5917  10  <.0001  
Wald  111.8582  10  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.18039  0.18069  0.9967  0.3181  1.198  0.841  1.707  
BUN_Gr_40_OR_Creat_Gr_2  1  0.65393  0.31318  4.3599  0.0368  1.923  1.041  3.553  
Triglycerides_Ls_150  1  0.25066  0.18393  1.8572  0.1730  1.285  0.896  1.843  
HDL_Ls_40_M_Ls_50_F  1  0.44489  0.18542  5.7568  0.0164  1.560  1.085  2.244  
Glucose_Gr_110  1  0.40056  0.16890  5.6242  0.0177  1.493  1.072  2.078  
Female  1  -0.32472  0.18979  2.9272  0.0871  0.723  0.498  1.048  
age_6  1  0.09683  0.01318  53.9589  <.0001  1.102  1.074  1.131  
White  1  0.28349  0.18630  2.3156  0.1281  1.328  0.922  1.913  
Married  1  -0.03510  0.18697  0.0352  0.8511  0.966  0.669  1.393  
Edu_Ls_7_year  1  0.00876  0.22644  0.0015  0.9691  1.009  0.647  1.572  
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5-year CAD Mortality Cox proportional Hazards Regression Model all together  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  CAD5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  149  4035  96.44  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
 
Model Fit Statistics  
 
                                                                                                                        Without                    With  
Criterion  Covariates    Covariates  
 
-2 LOG L  2444.961  2270.678  
AIC  2444.961  2336.678  
SBC  2444.961  2435.808  
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5-year CAD Mortality Cox proportional Hazards Regression Model all together  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  174.2834  33  <.0001  
Score  237.0109  33  <.0001  
Wald  197.1807  33  <.0001  
 
Analysis  of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  0.16848  0.18367  0.8414  0.3590  1.184  0.826  1.696  
BUN_Gr_40_OR_Creat_Gr_2  1  0.44046  0.31868  1.9103  0.1669  1.553  0.832  2.901  
Triglycerides_Ls_150  1  0.29833  0.18810  2.5153  0.1127  1.348  0.932  1.948  
HDL_Ls_40_M_Ls_50_F  1  0.28190  0.18949  2.2132  0.1368  1.326  0.914  1.922  
Glucose_Gr_110  1  0.25102  0.17528  2.0509  0.1521  1.285  0.912  1.812  
Female  1  -0.60233  0.20771  8.4095  0.0037  0.548  0.364  0.823  
age_6  1  0.06650  0.01493  19.8528  <.0001  1.069  1.038  1.100  
White  1  0.34194  0.19891  2.9551  0.0856  1.408  0.953  2.079  
Married  1  -0.03257  0.19114  0.0290  0.8647  0.968  0.666  1.408  
Edu_Ls_7_year  1  -0.0009597  0.23039  0.0000  0.9967  0.999  0.636  1.569  
DM_score  1  0.09210  0.04894  3.5418  0.0598  1.096  0.996  1.207  
Canx_score  1  -0.00208  0.06719  0.0010  0.9753  0.998  0.875  1.138  
HxAMI_score  1  0.19047  0.04845  15.4568  <.0001  1.210  1.100  1.330  
DM_suspect_score  1  0.05444  0.11358  0.2298  0.6317  1.056  0.845  1.319  
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Hx_Cu_Smoker_score  1  -0.00736  0.07955  0.0086  0.9263  0.993  0.849  1.160  
HTN_score  1  -0.04545  0.05327  0.7279  0.3936  0.956  0.861  1.061  
Obesity_score  1  0.01401  0.03363  0.1735  0.6770  1.014  0.949  1.083  
BP_Med  1  0.41116  0.17682  5.4069  0.0201  1.509  1.067  2.133  
ChxPain  1  0.65447  0.37787  2.9998  0.0833  1.924  0.917  4.035  
BP_S_Gr_160  1  0.28009  0.27187  1.0613  0.3029  1.323  0.777  2.255  
BP_D_Ls_90  1  0.29328  0.25166  1.3581  0.2439  1.341  0.819  2.196  
pulse_10  1  0.03437  0.06314  0.2963  0.5862  1.035  0.914  1.171  
ETOH_use  1  -0.16201  0.18553  0.7625  0.3825  0.850  0.591  1.223  
ADLscorebase  1  0.16116  0.26077  0.3819  0.5366  1.175  0.705  1.959  
GrossMobilityBase  1  -0.09155  0.10794  0.7193  0.3964  0.913  0.739  1.128  
PPDscorebase  1  -0.10821  0.11911  0.8254  0.3636  0.897  0.711  1.133  
SPMSQscorebase  1  -0.03426  0.06657  0.2649  0.6068  0.966  0.848  1.101  
BP_S_Gr_160_6  1  0.52484  0.30577  2.9462  0.0861  1.690  0.928  3.078  
BP_D_Ls_90_6  1  -0.21062  0.25511  0.6816  0.4090  0.810  0.491  1.336  
pulse_10_6  1  0.0003047  0.06299  0.0000  0.9961  1.000  0.884  1.132  
ADLscorebase_6  1  0.40059  0.15896  6.3509  0.0117  1.493  1.093  2.038  
GrossMobilityBase_6  1  -0.36493  0.09068  16.1975  <.0001  0.694  0.581  0.829  
PPDscorebase_6  1  -0.03778  0.09907  0.1455  0.7029  0.963  0.793  1.169  
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5-year Stroke Mortality Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Stroke5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  90  4094  97.85  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                       Without                   With  
Criterion  Covariates  Covariates  
 
-2 LOG L  1474.393  1462.836  
AIC  1474.393  1472.836  
SBC  1474.393  1485.335  
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5-year Stroke Mortality Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  11.5563  5  0.0414  
Score  16.6998  5  0.0051  
Wald  14.9155  5  0.0107  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.19782  0.22660  0.7621  0.3827  1.219  0.782  1.900  
BUN_Gr_40_OR_Creat_Gr_2  1  1.27034  0.37565  11.4359  0.0007  3.562  1.706  7.438  
Triglycerides_Ls_150  1  -0.35474  0.23884  2.2060  0.1375  0.701  0.439  1.120  
HDL_Ls_40_M_Ls_50_F  1  -0.22038  0.23346  0.8911  0.3452  0.802  0.508  1.268  
Glucose_Gr_110  1  0.09835  0.21567  0.2080  0.6484  1.103  0.723  1.684  
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5-year Stroke Mortality Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Stroke5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  90  4094  97.85  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
Without                 With  
Criterion     Covariates      Covariates  
-2 LOG L  1474.393  1432.814  
AIC  1474.393  1452.814  
SBC  1474.393  1477.813  
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5-year Stroke Mortality Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  41.5781  10  <.0001  
Score  51.1271  10  <.0001  
Wald  48.5744  10  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.00729  0.23708  0.0009  0.9755  1.007  0.633  1.603  
BUN_Gr_40_OR_Creat_Gr_2  1  1.05740  0.38409  7.5788  0.0059  2.879  1.356  6.112  
Triglycerides_Ls_150  1  -0.38818  0.23981  2.6202  0.1055  0.678  0.424  1.085  
HDL_Ls_40_M_Ls_50_F  1  -0.19601  0.23464  0.6978  0.4035  0.822  0.519  1.302  
Glucose_Gr_110  1  0.08755  0.21684  0.1630  0.6864  1.091  0.714  1.670  
Female  1  -0.14078  0.24479  0.3307  0.5652  0.869  0.538  1.404  
age_6  1  0.08317  0.01754  22.4735  <.0001  1.087  1.050  1.125  
White  1  0.32736  0.23963  1.8663  0.1719  1.387  0.867  2.219  
Married  1  0.13472  0.23813  0.3201  0.5716  1.144  0.717  1.825  
Edu_Ls_7_year  1  0.56861  0.25703  4.8940  0.0270  1.766  1.067  2.922  
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5-year Stroke Mortality Cox proportional Hazards Regression Model all together 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Stroke5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  90  4094  97.85  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
 
Model Fit Statistics  
 
Without  With  
Criterion  Covariates  Covariates  
-2 LOG L  1474.393  1362.300  
AIC  1474.393  1428.300  
SBC  1474.393  1510.793  
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5-year Stroke Mortality Cox proportional Hazards Regression Model all together  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  112.0930  33  <.0001  
Score  151.1676  33  <.0001  
Wald  121.7908  33  <.0001  
 
Analysis of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  -0.04051  0.24159  0.0281  0.8668  0.960  0.598  1.542  
BUN_Gr_40_OR_Creat_Gr_2  1  0.70195  0.38905  3.2554  0.0712  2.018  0.941  4.325  
Triglycerides_Ls_150  1  -0.30866  0.24398  1.6004  0.2058  0.734  0.455  1.185  
HDL_Ls_40_M_Ls_50_F  1  -0.30407  0.23929  1.6147  0.2038  0.738  0.462  1.179  
Glucose_Gr_110  1  -0.00278  0.22459  0.0002  0.9901  0.997  0.642  1.549  
Female  1  -0.57900  0.27131  4.5544  0.0328  0.560  0.329  0.954  
age_6  1  0.04600  0.01965  5.4781  0.0193  1.047  1.008  1.088  
White  1  0.33584  0.25785  1.6964  0.1928  1.399  0.844  2.319  
Married  1  0.21872  0.24118  0.8224  0.3645  1.244  0.776  1.997  
Edu_Ls_7_year  1  0.55008  0.26555  4.2908  0.0383  1.733  1.030  2.917  
DM_score  1  -0.04501  0.09117  0.2438  0.6215  0.956  0.800  1.143  
Canx_score  1  -0.19482  0.14013  1.9327  0.1645  0.823  0.625  1.083  
HxAMI_score  1  0.12889  0.07886  2.6716  0.1022  1.138  0.975  1.328  
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DM_suspect_score  1  -12.64392  473.12529  0.0007  0.9787  0.000  0.000  
Hx_Cu_Smoker_score  1  -0.24266  0.16387  2.1929  0.1387  0.785  0.569  1.082  
HTN_score  1  0.05471  0.05713  0.9169  0.3383  1.056  0.944  1.181  
Obesity_score  1  -0.04530  0.04728  0.9179  0.3380  0.956  0.871  1.049  
BP_Med  1  0.35940  0.22726  2.5009  0.1138  1.432  0.918  2.236  
ChxPain  1  0.56644  0.52296  1.1732  0.2787  1.762  0.632  4.911  
BP_S_Gr_160  1  -0.02762  0.34852  0.0063  0.9368  0.973  0.491  1.926  
BP_D_Ls_90  1  -0.34230  0.28431  1.4495  0.2286  0.710  0.407  1.240  
pulse_10  1  0.12691  0.07736  2.6911  0.1009  1.135  0.976  1.32 
ETOH_use  1  -0.19856  0.23997  0.6846  0.4080  0.820  0.512  1.312  
ADLscorebase  1  -11.80416  1254  0.0001  0.9925  0.000  0.000  
GrossMobilityBase  1  -0.35566  0.13173  7.2891  0.0069  0.701  0.541  0.907  
PPDscorebase  1  0.15184  0.13572  1.2516  0.2632  1.164  0.892  1.519  
SPMSQscorebase  1  -0.12029  0.08951  1.8061  0.1790  0.887  0.744  1.057  
BP_S_Gr_160_6  1  0.01607  0.39141  0.0017  0.9673  1.016  0.472  2.188  
BP_D_Ls_90_6  1  -0.10032  0.32388  0.0959  0.7568  0.905  0.479  1.707  
pulse_10_6  1  0.08489  0.07883  1.1595  0.2816  1.089  0.933  1.270  
ADLscorebase_6  1  0.44139  0.17349  6.4728  0.0110  1.555  1.107  2.185  
GrossMobilityBase_6  1  -0.20533  0.12080  2.8890  0.0892  0.814  0.643  1.032  
PPDscorebase_6  1  -0.11843  0.13381  0.7833  0.3761  0.888  0.683  1.155  
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5-year HF Mortality Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  HF5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  80  4104  98.09  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
Without                With  
Criterion      Covariates    Covariates  
-2 LOG L  1310.413  1255.775  
AIC  1310.413  1265.775  
SBC  1310.413  1277.685  
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5-year HF Mortality Cox proportional Hazards Regression Model w/ blood   
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  54.6388  5  <.0001  
Score  109.7353  5  <.0001  
Wald  77.5399  5  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  -0.17920  0.24321  0.5429  0.4612  0.836  0.519  1.346  
BUN_Gr_40_OR_Creat_Gr_2  1  2.11027  0.28937  53.1823  <.0001  8.251  4.679  14.548  
Triglycerides_Ls_150  1  0.40950  0.24957  2.6923  0.1008  1.506  0.923  2.456  
HDL_Ls_40_M_Ls_50_F  1  0.28927  0.25639  1.2730  0.2592  1.335  0.808  2.207  
Glucose_Gr_110  1  0.80196  0.24051  11.1182  0.0009  2.230  1.392  3.573  
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5-year HF Mortality Cox proportional Hazards Regression Model w/ blood  + demo 
 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  HF5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  80  4104  98.09  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
Without                With  
Criterion      Covariates     Covariates  
-2 LOG L  1310.413  1205.594  
AIC  1310.413  1225.594  
SBC  1310.413  1249.414  
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5-year HF Mortality Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  104.8192  10  <.0001  
Score  171.5610  10  <.0001  
Wald  136.9073  10  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  -0.54926  0.25972  4.4725  0.0344  0.577  0.347  0.961  
BUN_Gr_40_OR_Creat_Gr_2  1  1.74272  0.30472  32.7079  <.0001  5.713  3.144  10.381  
Triglycerides_Ls_150  1  0.26953  0.25164  1.1473  0.2841  1.309  0.800  2.144  
HDL_Ls_40_M_Ls_50_F  1  0.31877  0.25760  1.5313  0.2159  1.375  0.830  2.279  
Glucose_Gr_110  1  0.70870  0.24225  8.5585  0.0034  2.031  1.264  3.266  
Female  1  -0.83482  0.25676  10.5710  0.0011  0.434  0.262  0.718  
age_6  1  0.10909  0.01814  36.1513  <.0001  1.115  1.076  1.156  
White  1  0.09843  0.24542  0.1609  0.6884  1.103  0.682  1.785  
Married  1  -0.51198  0.25755  3.9518  0.0468  0.599  0.362  0.993  
Edu_Ls_7_year  1  -0.07325  0.30534  0.0576  0.8104  0.929  0.511  1.691  
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5-year HF Mortality Cox proportional Hazards Regression Model all together   
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  HF5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  80  4104  98.09  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
Without                With  
Criterion     Covariates   Covariates  
-2 LOG L  1310.413  1146.297  
AIC  1310.413  1212.297  
SBC  1310.413  1290.904  
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5-year HF Mortality Cox proportional Hazards Regression Model all together    
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  164.1162  33  <.0001  
Score  243.9352  33  <.0001  
Wald  188.5526  33  <.0001  
 
Analysis  of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  -0.62722  0.26917  5.4296  0.0198  0.534  0.315  0.905  
BUN_Gr_40_OR_Creat_Gr_2  1  1.50097  0.31886  22.1581  <.0001  4.486  2.401  8.381  
Triglycerides_Ls_150  1  0.29983  0.26206  1.3090  0.2526  1.350  0.808  2.256  
HDL_Ls_40_M_Ls_50_F  1  0.06592  0.26801  0.0605  0.8057  1.068  0.632  1.806  
Glucose_Gr_110  1  0.48818  0.25227  3.7449  0.0530  1.629  0.994  2.671  
Female  1  -1.20076  0.28572  17.6620  <.0001  0.301  0.172  0.527  
age_6  1  0.07373  0.02021  13.3072  0.0003  1.077  1.035  1.120  
White  1  0.21203  0.27198  0.6078  0.4356  1.236  0.725  2.107  
Married  1  -0.49548  0.26497  3.4969  0.0615  0.609  0.362  1.024  
Edu_Ls_7_year  1  -0.18520  0.31927  0.3365  0.5619  0.831  0.444  1.554  
DM_score  1  0.20410  0.05598  13.2926  0.0003  1.226  1.099  1.369  
Canx_score  1  0.00820  0.09248  0.0079  0.9294  1.008  0.841  1.209  
HxAMI_score  1  0.19985  0.06715  8.8573  0.0029  1.221  1.071  1.393  
DM_suspect_score  1  0.02778  0.16851  0.0272  0.8690  1.028  0.739  1.431  
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Hx_Cu_Smoker_score  1  0.04542  0.10153  0.2001  0.6546  1.046  0.858  1.277  
HTN_score  1  -0.08493  0.08195  1.0741  0.3000  0.919  0.782  1.079  
Obesity_score  1  -0.00461  0.04713  0.0096  0.9221  0.995  0.908  1.092  
BP_Med  1  -0.03263  0.25724  0.0161  0.8991  0.968  0.585  1.602  
ChxPain  1  0.49426  0.54439  0.8243  0.3639  1.639  0.564  4.765  
BP_S_Gr_160  1  -0.29616  0.37541  0.6223  0.4302  0.744  0.356  1.552  
BP_D_Ls_90  1  -0.10933  0.32373  0.1141  0.7356  0.896  0.475  1.691  
pulse_10  1  0.17293  0.08815  3.8481  0.0498  1.189  1.000  1.413  
ETOH_use  1  -0.45790  0.27084  2.8583  0.0909  0.633  0.372  1.076  
ADLscorebase  1  -9.16952  510.26784  0.0003  0.9857  0.000  0.000  
GrossMobilityBase  1  -0.05328  0.14383  0.1372  0.7111  0.948  0.715  1.257  
PPDscorebase  1  -0.00405  0.15911  0.0006  0.9797  0.996  0.729  1.360  
SPMSQscorebase  1  0.00600  0.09023  0.0044  0.9470  1.006  0.843  1.201  
BP_S_Gr_160_6  1  0.57719  0.40113  2.0705  0.1502  1.781  0.811  3.909  
BP_D_Ls_90_6  1  0.36016  0.42591  0.7151  0.3978  1.434  0.622  3.303  
pulse_10_6  1  0.04230  0.08390  0.2542  0.6141  1.043  0.885  1.230  
ADLscorebase_6  1  0.09560  0.39520  0.0585  0.8089  1.100  0.507  2.387  
GrossMobilityBase_6  1  -0.41218  0.12844  10.2985  0.0013  0.662  0.515  0.852  
PPDscorebase_6  1  0.02232  0.13541  0.0272  0.8691  1.023  0.784  1.333  
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5-year Other Deaths Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Other5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  536  3648  87.19  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                            Without                 With  
Criterion     Covariates     Covariates  
 
-2 LOG L  8798.711  8694.421  
AIC  8798.711  8704.421  
SBC  8798.711  8725.842  
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5-year Other Deaths Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  104.2892  5  <.0001  
Score  127.0367  5  <.0001  
Wald  119.0430  5  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.52871  0.09112  33.6666  <.0001  1.697  1.419  2.029  
BUN_Gr_40_OR_Creat_Gr_2  1  1.10849  0.15981  48.1103  <.0001  3.030  2.215  4.144  
Triglycerides_Ls_150  1  0.29612  0.09791  9.1472  0.0025  1.345  1.110  1.629  
HDL_Ls_40_M_Ls_50_F  1  -0.04685  0.09560  0.2402  0.6241  0.954  0.791  1.151  
Glucose_Gr_110  1  0.23751  0.08826  7.2423  0.0071  1.268  1.067  1.508  
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5-year Other Deaths Cox proportional Hazards Regression Model w/ blood + demo 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Other5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  536  3648  87.19  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                          Without                   With  
Criterion    Covariates     Covariates  
-2 LOG L  8798.711  8590.815  
AIC  8798.711  8610.815  
SBC  8798.711  8653.657  
 
   
 
137 
5-year Other Deaths Cox proportional Hazards Regression Model w/ blood + demo  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
 
Likelihood Ratio  207.8954  10  <.0001  
Score  244.1674  10  <.0001  
Wald  235.5889  10  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.31839  0.09490  11.2567  0.0008  1.375  1.142  1.656  
BUN_Gr_40_OR_Creat_Gr_2  1  0.86619  0.16339  28.1043  <.0001  2.378  1.726  3.275  
Triglycerides_Ls_150  1  0.29410  0.09818  8.9728  0.0027  1.342  1.107  1.627  
HDL_Ls_40_M_Ls_50_F  1  0.00744  0.09588  0.0060  0.9381  1.007  0.835  1.216  
Glucose_Gr_110  1  0.20293  0.08844  5.2648  0.0218  1.225  1.030  1.457  
Female  1  -0.64206  0.09761  43.2710  <.0001  0.526  0.435  0.637  
age_6  1  0.05309  0.00730  52.8282  <.0001  1.055  1.040  1.070  
White  1  0.07952  0.09412  0.7138  0.3982  1.083  0.900  1.302  
Married  1  -0.29503  0.09717  9.2199  0.0024  0.745  0.615  0.901  
Edu_Ls_7_year  1  0.19363  0.11285  2.9438  0.0862  1.214  0.973  1.514  
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5-year Other Deaths Cox proportional Hazards Regression Model w/ blood all together 
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  Other5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  536  3648  87.19  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                           Without                 With  
Criterion     Covariates     Covariates  
-2 LOG L  8798.711  8439.145  
AIC  8798.711  8505.145  
SBC  8798.711  8646.522  
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5-year Other Deaths Cox proportional Hazards Regression Model w/ blood all together 
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  359.5651  33  <.0001  
Score  426.5801  33  <.0001  
Wald  393.3818  33  <.0001  
 
Analysis  of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  0.22600  0.09618  5.5218  0.0188  1.254  1.038  1.514  
BUN_Gr_40_OR_Creat_Gr_2  1  0.67800  0.16795  16.2967  <.0001  1.970  1.417  2.738  
Triglycerides_Ls_150  1  0.32747  0.09946  10.8396  0.0010  1.387  1.142  1.686  
HDL_Ls_40_M_Ls_50_F  1  -0.02809  0.09720  0.0835  0.7726  0.972  0.804  1.176  
Glucose_Gr_110  1  0.12974  0.09104  2.0308  0.1541  1.139  0.952  1.361  
Female  1  -0.75188  0.10524  51.0417  <.0001  0.471  0.384  0.579  
age_6  1  0.02471  0.00799  9.5612  0.0020  1.025  1.009  1.041  
White  1  0.10766  0.09917  1.1785  0.2777  1.114  0.917  1.353  
Married  1  -0.22809  0.09806  5.4110  0.0200  0.796  0.657  0.965  
Edu_Ls_7_year  1  0.15421  0.11532  1.7883  0.1811  1.167  0.931  1.463  
DM_score  1  0.03536  0.02996  1.3932  0.2379  1.036  0.977  1.099  
Canx_score  1  0.07636  0.02907  6.9011  0.0086  1.079  1.020  1.143  
HxAMI_score  1  0.01191  0.04041  0.0869  0.7682  1.012  0.935  1.095  
DM_suspect_score  1  0.02919  0.06674  0.1913  0.6618  1.030  0.903  1.174  
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Hx_Cu_Smoker_score  1  0.09190  0.03191  8.2927  0.0040  1.096  1.030  1.167  
HTN_score  1  -0.04036  0.02778  2.1109  0.1463  0.960  0.910  1.014  
Obesity_score  1  -0.01488  0.01887  0.6219  0.4304  0.985  0.949  1.022  
BP_Med  1  0.01424  0.09824  0.0210  0.8848  1.014  0.837  1.230  
ChxPain  1  -0.11925  0.28504  0.1750  0.6757  0.888  0.508  1.552  
BP_S_Gr_160  1  -0.22939  0.15341  2.2358  0.1348  0.795  0.589  1.074  
BP_D_Ls_90  1  -0.08947  0.12080  0.5486  0.4589  0.914  0.722  1.159  
pulse_10  1  0.08814  0.03339  6.9684  0.0083  1.092  1.023  1.166 
ETOH_use  1  0.09252  0.09349  0.9793  0.3224  1.097  0.913  1.318  
ADLscorebase  1  0.15747  0.17537  0.8063  0.3692  1.171  0.830  1.651  
GrossMobilityBase  1  -0.03070  0.05902  0.2705  0.6030  0.970  0.864  1.089  
PPDscorebase  1  -0.08941  0.06730  1.7651  0.1840  0.914  0.801  1.043  
SPMSQscorebase  1  0.00493  0.03466  0.0203  0.8868  1.005  0.939  1.076  
BP_S_Gr_160_6  1  0.07361  0.18452  0.1591  0.6899  1.076  0.750  1.545  
BP_D_Ls_90_6  1  -0.36711  0.13294  7.6253  0.0058  0.693  0.534  0.899  
pulse_10_6  1  -0.03436  0.03312  1.0763  0.2995  0.966  0.905  1.031  
ADLscorebase_6  1  0.21535  0.11543  3.4803  0.0621  1.240  0.989  1.555  
GrossMobilityBase_6  1  -0.39061  0.04727  68.2699  <.0001  0.677  0.617  0.742  
PPDscorebase_6  1  0.10191  0.04997  4.1592  0.0414  1.107  1.004  1.221  
 
 
 
 
 
 
 
 
 
 
   
 
14
1 
 
 
5-year All Cause Mortality Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  obs5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  1043  3141  75.07  
 
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                       Without                   With  
Criterion  Covariates  Covariates  
-2 LOG L  17110.887  16912.111  
AIC  17110.887  16922.111  
SBC  17110.887  16946.860  
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5-year All Cause Mortality Cox proportional Hazards Regression Model w/ blood  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  198.7761  5  <.0001  
Score  269.8251  5  <.0001  
Wald  244.9357  5  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
 
LDL_Ls_200  1  0.41126  0.06529  39.6705  <.0001  1.509  1.327  1.715  
BUN_Gr_40_OR_Creat_Gr_2  1  1.22705  0.10791  129.2953  <.0001  3.411  2.761  4.215  
Triglycerides_Ls_150  1  0.15556  0.06945  5.0164  0.0251  1.168  1.020  1.339  
HDL_Ls_40_M_Ls_50_F  1  0.05651  0.06898  0.6713  0.4126  1.058  0.924  1.211  
Glucose_Gr_110  1  0.34139  0.06346  28.9405  <.0001  1.407  1.242  1.593  
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5-year All Cause Mortality Cox proportional Hazards Regression Model w/ blood + demo 
 
The PHREG Procedure  
 
Model Information  
 
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  obs5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  1043  3141  75.07  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                        Without                    With  
Criterion  Covariates    Covariates  
-2 LOG L  17110.887  16614.298  
AIC  17110.887  16634.298  
SBC  17110.887  16683.796  
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5-year All Cause Mortality Cox proportional Hazards Regression Model w/ blood + demo 
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  496.5896  10  <.0001  
Score  616.3185  10  <.0001  
Wald  587.2379  10  <.0001  
 
Analysis of Maximum Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr > ChiSq  Ratio  Confidence Limits  
LDL_Ls_200  1  0.15828  0.06825  5.3790  0.0204  1.171  1.025  1.339  
BUN_Gr_40_OR_Creat_Gr_2  1  0.92866  0.11073  70.3420  <.0001  2.531  2.037  3.145  
Triglycerides_Ls_150  1  0.13220  0.06961  3.6068  0.0575  1.141  0.996  1.308  
HDL_Ls_40_M_Ls_50_F  1  0.11536  0.06911  2.7860  0.0951  1.122  0.980  1.285  
Glucose_Gr_110  1  0.30250  0.06363  22.5990  <.0001  1.353  1.195  1.533  
Female  1  -0.65263  0.07035  86.0567  <.0001  0.521  0.454  0.598  
age_6  1  0.07364  0.00513  206.3928  <.0001  1.076  1.066  1.087  
White  1  0.10032  0.06786  2.1858  0.1393  1.106  0.968  1.263  
Married  1  -0.20715  0.07000  8.7567  0.0031  0.813  0.709  0.932  
Edu_Ls_7_year  1  0.17150  0.08097  4.4863  0.0342  1.187  1.013  1.391  
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5-year All Cause Mortality Cox proportional Hazards Regression Model all together  
  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  obs5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  1043  3141  75.07  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
 
Model Fit Statistics  
 
                                                                                                                       Without                    With  
Criterion  Covariates  Covariates  
-2 LOG L  17110.887  16308.145  
AIC  17110.887  16374.145  
SBC  17110.887  16537.491  
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5-year All Cause Mortality Cox proportional Hazards Regression Model all together  
  
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  802.7419  33  <.0001  
Score  979.7613  33  <.0001  
Wald  878.6071  33  <.0001  
 
 
Analysis  of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence  Limits  
LDL_Ls_200  1  0.07791  0.06923  1.2663  0.2605  1.081  0.944  1.238  
BUN_Gr_40_OR_Creat_Gr_2  1  0.71070  0.11342  39.2662  <.0001  2.035  1.630  2.542  
Triglycerides_Ls_150  1  0.16963  0.07085  5.7323  0.0167  1.185  1.031  1.361  
HDL_Ls_40_M_Ls_50_F  1  0.02764  0.07035  0.1543  0.6944  1.028  0.896  1.180  
Glucose_Gr_110  1  0.20132  0.06554  9.4367  0.0021  1.223  1.076  1.391  
Female  1  -0.83833  0.07632  120.6452  <.0001  0.432  0.372  0.502  
age_6  1  0.04275  0.00563  57.7126  <.0001  1.044  1.032  1.055  
White  1  0.12971  0.07218  3.2300  0.0723  1.139  0.988  1.312  
Married  1  -0.14881  0.07075  4.4243  0.0354  0.862  0.750  0.990  
Edu_Ls_7_year  1  0.13362  0.08252  2.6220  0.1054  1.143  0.972  1.344  
DM_score  1  0.06280  0.01977  10.0881  0.0015  1.065  1.024  1.107  
Canx_score  1  0.02548  0.02341  1.1845  0.2764  1.026  0.980  1.074  
HxAMI_score  1  0.07650  0.02411  10.0677  0.0015  1.080  1.030  1.132  
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DM_suspect_score  1  -0.00602  0.05191  0.0135  0.9077  0.994  0.898  1.100  
Hx_Cu_Smoker_score  1  0.06678  0.02450  7.4287  0.0064  1.069  1.019  1.122  
HTN_score  1  -0.02331  0.01951  1.4279  0.2321  0.977  0.940  1.015  
Obesity_score  1  -0.02065  0.01351  2.3366  0.1264  0.980  0.954  1.006  
BP_Med  1  0.07892  0.06927  1.2979  0.2546  1.082  0.945  1.239  
ChxPain  1  0.32759  0.16677  3.8584  0.0495  1.388  1.001  1.924  
BP_S_Gr_160  1  -0.07653  0.10576  0.5236  0.4693  0.926  0.753  1.140  
BP_D_Ls_90  1  -0.07086  0.08642  0.6722  0.4123  0.932  0.786  1.104  
pulse_10  1  0.08040  0.02401  11.2132  0.0008  1.084  1.034  1.136  
ETOH_use  1  -0.04945  0.06807  0.5277  0.4676  0.952  0.833  1.088  
ADLscorebase  1  0.03499  0.13892  0.0634  0.8011  1.036  0.789  1.360  
GrossMobilityBase  1  -0.07355  0.04106  3.2089  0.0732  0.929  0.857  1.007  
PPDscorebase  1  -0.04041  0.04573  0.7811  0.3768  0.960  0.878  1.050  
SPMSQscorebase  1  -0.01638  0.02482  0.4356  0.5092  0.984  0.937  1.033  
BP_S_Gr_160_6  1  0.10205  0.12438  0.6732  0.4119  1.107  0.868  1.413  
BP_D_Ls_90_6  1  -0.27449  0.09490  8.3665  0.0038  0.760  0.631  0.915  
pulse_10_6  1  0.02011  0.02369  0.7200  0.3961  1.020  0.974  1.069  
ADLscorebase_6  1  0.25957  0.07567  11.7665  0.0006  1.296  1.118  1.504  
GrossMobilityBase_6  1  -0.37924  0.03407  123.8925  <.0001  0.684  0.640  0.732  
PPDscorebase_6  1  0.01990  0.03701  0.2891  0.5908  1.020  0.949  1.097  
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5-year All Cause Mortality Cox proportional Hazards Regression Model all together  
  
 
The PHREG Procedure  
 
Model Information  
Data Set  WORK.EPESE_6_3  
Dependent Variable  day5y_6  
Censoring Variable  obs5y_6  
Censoring Value(s)  0  
Ties Handling  BRESLOW  
 
 
Summary of the Number of Event and Censored Values  
 
Percent  
Total  Event  Censored  Censored  
4184  1043  3141  75.07  
 
Convergence Status  
Convergence criterion (GCONV=1E-8) satisfied.  
 
Model Fit Statistics  
 
                                                                                                                         Without                   With  
Criterion    Covariates    Covariates  
-2 LOG L  17110.887  16308.145  
AIC  17110.887  16374.145  
SBC  17110.887  16537.491  
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        5-year All Cause Mortality Cox proportional Hazards Regression Model all together  
  
 
The PHREG Procedure  
 
Testing Global Null Hypothesis: BETA=0  
 
Test  Chi-Square  DF  Pr > ChiSq  
Likelihood Ratio  802.7419  33  <.0001  
Score  979.7613  33  <.0001  
Wald  878.6071  33  <.0001  
 
Analysis  of Maximum  Likelihood Estimates  
 
Parameter  Standard  Hazard  95% 
Hazard  Ratio  
Variable  DF  Estimate  Error  Chi-Square  Pr  > ChiSq  Ratio  Confidence 
 Limits  
LDL_Ls_200  1  0.07791  0.06923  1.2663  0.2605  1.081  0.944  1.238  
BUN_Gr_40_OR_Creat_Gr_2  1  0.71070  0.11342  39.2662  <.0001  2.035  1.630  2.542  
Triglycerides_Ls_150  1  0.16963  0.07085  5.7323  0.0167  1.185  1.031  1.361  
HDL_Ls_40_M_Ls_50_F  1  0.02764  0.07035  0.1543  0.6944  1.028  0.896  1.180  
Glucose_Gr_110  1  0.20132  0.06554  9.4367  0.0021  1.223  1.076  1.391  
Female  1  -0.83833  0.07632  120.6452  <.0001  0.432  0.372  0.502  
age_6  1  0.04275  0.00563  57.7126  <.0001  1.044  1.032  1.055  
White  1  0.12971  0.07218  3.2300  0.0723  1.139  0.988  1.312  
Married  1  -0.14881  0.07075  4.4243  0.0354  0.862  0.750  0.990  
Edu_Ls_7_year  1  0.13362  0.08252  2.6220  0.1054  1.143  0.972  1.344  
DM_score  1  0.06280  0.01977  10.0881  0.0015  1.065  1.024  1.107  
Canx_score  1  0.02548  0.02341  1.1845  0.2764  1.026  0.980  1.074  
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HxAMI_score  1  0.07650  0.02411  10.0677  0.0015  1.080  1.030  1.132  
DM_suspect_score  1  -0.00602  0.05191  0.0135  0.9077  0.994  0.898  1.100  
Hx_Cu_Smoker_score  1  0.06678  0.02450  7.4287  0.0064  1.069  1.019  1.122  
HTN_score  1  -0.02331  0.01951  1.4279  0.2321  0.977  0.940  1.015  
Obesity_score  1  -0.02065  0.01351  2.3366  0.1264  0.980  0.954  1.006  
BP_Med  1  0.07892  0.06927  1.2979  0.2546  1.082  0.945  1.239  
ChxPain  1  0.32759  0.16677  3.8584  0.0495  1.388  1.001  1.924  
BP_S_Gr_160  1  -0.07653  0.10576  0.5236  0.4693  0.926  0.753  1.140  
BP_D_Ls_90  1  -0.07086  0.08642  0.6722  0.4123  0.932  0.786  1.104  
pulse_10  1  0.08040  0.02401  11.2132  0.0008  1.084  1.034  1.136  
ETOH_use  1  -0.04945  0.06807  0.5277  0.4676  0.952  0.833  1.088  
ADLscorebase  1  0.03499  0.13892  0.0634  0.8011  1.036  0.789  1.360  
GrossMobilityBase  1  -0.07355  0.04106  3.2089  0.0732  0.929  0.857  1.007  
PPDscorebase  1  -0.04041  0.04573  0.7811  0.3768  0.960  0.878  1.050  
SPMSQscorebase  1  -0.01638  0.02482  0.4356  0.5092  0.984  0.937  1.033  
BP_S_Gr_160_6  1  0.10205  0.12438  0.6732  0.4119  1.107  0.868  1.413  
BP_D_Ls_90_6  1  -0.27449  0.09490  8.3665  0.0038  0.760  0.631  0.915  
pulse_10_6  1  0.02011  0.02369  0.7200  0.3961  1.020  0.974  1.069  
ADLscorebase_6  1  0.25957  0.07567  11.7665  0.0006  1.296  1.118  1.504  
GrossMobilityBase_6  1  -0.37924  0.03407  123.8925  <.0001  0.684  0.640  0.732  
PPDscorebase_6  1  0.01990  0.03701  0.2891  0.5908  1.020  0.949  1.097  
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APPENDIX 5:  HIC Exemption from Review   
Yale University 
Human Investigation Committee 
School of Medicine 
47 College Street, Suite 204   Telephone: 203/785-4688 
New Haven, Connecticut 06520-8010   Fax: 203/785-
2847 
 
REQUEST FOR EXEMPTION FROM COMMITTEE REVIEW 
 
Title of Project:  Examination of the Prognostic Value of HDL-C 
Levels on Cardiovascular Morbidity, Mortality, and Overall Health 
Status in an Elderly Population 
 
Principal Investigator:  Lisa M.  Millman  
 
Dept:  Yale School of Medicine—Dept of Internal Medicine, Cardiology 
Section 
 
PI’s Association or Status with Yale: Yale Medical Student 
 
Other Investigator(s):   
JoAnne M.  Foody, MD—Dept of Internal Medicine, Cardiology Section 
 
Certain research activities may be exempt from review, if approved by 
the HIC Chair or his/her designee and confirmed in writing to the 
Investigator.   Research may be exempt from review when the only 
involvement of human subjects in the research falls into one of the 
categories noted below. 
 
• 45 CFR 46.101(b)(4)Research involving the collection or study of 
existing data, documents, records, pathological specimens, or 
diagnostic specimens, if these sources are publicly available or if 
the information is recorded by the investigator in such a manner 
that subjects cannot be identified, directly or through identifiers 
linked to the subjects.   “Existing” is the keyword here.   It 
means that all the data, documents, etc.  must be “on the 
shelf” when the study is started and no additional data, 
etc.  may be added to the set of data.     
1) Describe the purpose of the study 
2) Describe how data will be recorded so that subjects will not 
be identified 
3) Describe the procedures that will be used. 
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Statement of Hypothesis and Specific Aims 
Morbidity and mortality from cardiovascular disease is a major health 
problem in the United States with elderly adults (>65 years) 
experiencing the greatest number of coronary heart disease related 
events and deaths 1.  Older adults shoulder the highest risks 
associated with cardiovascular disease and stand the most chance to 
benefit if predictors of risk can be stratified within the this population 
and appropriate interventions put into place.  Serum cholesterol and 
high-density lipoprotein (HDL-C) levels seem to be a good place to start 
given their strong prognostic value in a middle-aged population 2-4, but 
their value in an elderly population is controversial with conflicting 
data 3-6.   
 
This study proposal seeks to build upon previous studies in an elderly 
population using data from the Established Populations for 
Epidemiologic Studies of the Elderly (EPESE), which provides a rich 
source of longitudinal clinical, functional, and social information on 
individuals >65 years old.  Over 5,000 of these participants had a 
blood draw at the 6th annual follow-up providing serum cholesterol, 
HDL-C, and triglycerides, as well as additional biochemical variables.  
Since the study has been closed at all sites since 1992, it is now 
possible to review complete 10 year mortality data in this well-studied 
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population.   This proposal has the following aims utilizing this data 
available from the EPESE project: 
 
AIM 1: To determine if HDL-C levels and HDL-C to total serum 
cholesterol ratios are prognostic for cardiovascular morbidity and 
mortality in the entire EPESE population with serum samples  
AIM 2: To evaluate the degree to which HDL-C levels and HDL-C to 
total serum cholesterol ratios are associated with outcomes in those 
with prior cardiovascular history (recurrence) vs.  those without prior 
history (new events)  
AIM 3: To determine if HDL-C levels and HDL-C to total serum 
cholesterol ratios correlate with other outcome measures of overall 
health status including number of chronic conditions, depressive 
symptoms, cognitive and physical functioning 
 
Research Design and Methods 
Data Collection 
Studies of the Elderly (EPESE), initiated in 1980 by the Epidemiology, 
Demography, and Biometry Program (EDBP) at the National Institutes 
of Aging to study health, social, psychological, and economic aspects 
of the elderly.  EPESE incorporates cross-sectional data and This 
project will use data from the Established Populations for 
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Epidemiologic continued surveillance beginning in 1981 with annual 
follow-up of more than 10,000 subjects age 65 and older.   Study 
participants were recruited from 3 communities: East Boston, MA, 
Iowa and Washington Counties, Iowa; and New Haven, CT between 
1981 and 1982 with an additional 4th site in the Piedmont area of 
North Carolina added in 1986.   In East Boston and the Iowa counties, 
the study samples represented the total populations 65 years of age 
and older; in New Haven, the sample derived from a stratified (by 
housing type and sex) random sample of residents.   Between 80 and 
84% of eligible persons in the three communities participated.   
Participants were followed from 1981 to 1988 with annual in-person 
(1982, 1985, 1988) and telephone interviews (1989 and 1990/91).   
During the in-person interviews (which were done at baseline and at 
the 3rd and 6th follow-up points), participants were asked about their 
health habits, functional status, chronic conditions, and 
hospitalization history and had their blood pressure measured at 
home.   
 
Important to this proposal, in 1987-88, (sixth annual follow-up) blood 
samples were obtained from  65% of the 6,566 surviving participants 
greater than or equal to 71 years of age providing 4,128  useful 
measures for total cholesterol, HDL-C, glucose, Hgb A1c and albumin.  
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Participants were non-fasting at the time of the blood draw, but fasting 
serum cholesterol and HDL-C values have been shown to correlate 
with post-prandial values in both normal controls (non-elevated at 
baseline) and those with baseline hypercholesterolemia 15.   
 
All data examined by this study has already been coded by the main 
EPESE research center such that each individual has received their 
own number and is only identifiable by that number and by particular 
site area (East Boston, Iowa, New Haven, North Carolina).  Data meets 
HIPAA de-identification criteria.   The data collection for the EPESE 
project has been closed at all sites in 1991-2, but the mortality 
continued to be recorded and coded past that time (as outlined under 
Aim 1: Mortality section below) by the EPESE research center 16.   
 
Analysis 
AIM 1: To determine if HDL-C levels and HDL-C to total serum 
cholesterol ratios are prognostic for cardiovascular morbidity and 
mortality in the entire EPESE population with serum samples  
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The major variables of this research to assess the predictive value of 
HDL-C and HDL-C to total cholesterol ratios will be determined as 
follows: 
• Age: “elderly” will be defined as individuals age 65 and older 
• HDL Cholesterol: The ratio of HDL-C to total serum cholesterol 
will be calculated.  HDL-C will be stratified by sex and further 
broken down into 3 groups  
  For men: <=37 mg/dL, 38-47 mg/dL, >47 mg/dL  5 
  For women: <=40 mg/dL, 41-50 mg/dL, >50 mg/dL  5 
• Total Cholesterol: Will be stratified into 3 groups <200 mg/dL, 
200-240 mg/dL, and >=240 mg/dL 5 
• Triglycerides: Will be stratified into 2 groups <150 mg/dL and 
>150 mg/dL 
• Mortality: A mortality surveillance system is in place at each 
EPESE center.   Information indicating a death may be acquired 
from obituary notices, hospitalization records, proxy information 
or other sources.  Death certificates are obtained at all centers 
and the cause of death is reviewed and coded.  Mortality (overall 
survival) will be considered the ultimate end point with the 
alternate end point of cardiovascular event-free survival.  
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Mortality will be grouped by survival at 1 year, 5 years and 10 
years. 
 
AIM 2: To evaluate the degree to which HDL-C levels and HDL-C to 
total serum cholesterol ratios are associated with outcomes in those 
with prior cardiovascular history (recurrence) vs.  those without prior 
history (new events)  
 
The most frequently utilized co-variants in EPESE cohorts include age, 
systolic blood pressure, presence of stable angina, history of medically 
treated hypertension, smoking history and history of diabetes mellitus 
and myocardial infarction 5.  Co-variants selected from following 
descriptively reported data will be used to determine and adjust for 
additional risk factors of cardiovascular disease in a multi-variable 
logistic regression model: 
• Clinical History: Age, hypertension, diabetes mellitus, prior MI, 
prior heart failure, current smoker, history of cerebrovascular 
disease, peripheral vascular disease, and hypercholesterolemia 
• Behavioral Covariates: Pack-years of smoking; body mass index; 
alcohol consumption in the past month; physical activity 
 
  158 
  
AIM 3: To determine if HDL-C levels and HDL-C to total serum 
cholesterol ratios correlate with other outcome measures of overall 
health status including number of chronic conditions, depressive 
symptoms, cognitive and physical functioning 
 
Scored components of health status will be used to determine 
participant’s overall functioning which will be examined in the context 
of HDL-C and HDL-C and serum cholesterol ratios.  The following 
health status assessments are  descriptive reports obtained through a 
systematic interviewing process of EPESE participants: 
 
• Health Status: Health status includes the number of chronic 
conditions (high blood pressure, heart attack, stroke, diabetes, 
cancer, a broken hip, or other broken bones); depressive 
symptoms (Center for Epidemiologic Studies Depression scale 
score; cognitive function (short portable Mental Status 
Questionnaire score); and physical function measured with three 
self-report scales looking at basic activities of daily living, gross 
mobility, and more difficult tasks.    
 
Since elderly population has the greatest risk of morbidity and 
mortality from cardiovascular disease, this population would obtain 
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the most benefit from an easy means of assessing risk and 
implementing an appropriate intervention.  HDL-C and its relationship 
to total cholesterol is good candidate for assessing risk of 
cardiovascular disease in an elderly population since it has been 
shown to have an excellent prognostic value in a middle-age 
population, is simple to obtain with a blood test, and is a potentially 
modifiable risk factor through lifestyle and/or pharmaceutical 
intervention.  By utilizing the vast data available in EPESE, the value 
of HDL-C and HDL-C to total cholesterol ratios in assessing risk can 
be examined in those with existing cardiovascular disease and those 
with a new onset.  By determining the prognostic value of these simple 
blood tests, clinicians could better assess elderly patient risk for new 
or recurrent cardiovascular disease and act to appropriately manage 
or prevent its potential morbidity and mortality. 
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